BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750. [PMID: 10072408 DOI: 10.1056/nejm199903113401001] [Cited by in Crossref: 2164] [Cited by in F6Publishing: 676] [Article Influence: 94.1] [Reference Citation Analysis]
Number Citing Articles
1 Liang TJ, Ghany M. Hepatitis B e Antigen--the dangerous endgame of hepatitis B. N Engl J Med 2002;347:208-10. [PMID: 12124411 DOI: 10.1056/NEJMe020060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lee B, Liu K, Lin C, Kao C. Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study. Eur Radiol 2017;27:4482-9. [DOI: 10.1007/s00330-017-4893-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
3 Di Bisceglie AM, Strasberg S. A common staging system for hepatocellular carcinoma. Hepatology 2004;39:550-1. [DOI: 10.1002/hep.20072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
4 Li C, Li X, Wang H, Guo X, Xue J, Wang X, Ni J. MicroRNA-22-3p and MicroRNA-149-5p Inhibit Human Hepatocellular Carcinoma Cell Growth and Metastasis Properties by Regulating Methylenetetrahydrofolate Reductase. CIMB 2022;44:952-62. [DOI: 10.3390/cimb44020063] [Reference Citation Analysis]
5 Bhat M, Hassanain M, Simoneau E, Tzimas GN, Chaudhury P, Deschenes M, Valenti D, Ghali P, Wong P, Cabrera T. Magnitude of change in alpha-fetoprotein in response to transarterial chemoembolization predicts survival in patients undergoing liver transplantation for hepatocellular carcinoma. Curr Oncol. 2013;20:265-272. [PMID: 24155631 DOI: 10.3747/co.20.1270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Beutler BD, Ulanja MB, Krishan R, Aluru V, Ndukwu ML, Hagen MM, Dupin ZD, Willyard CE, Moody AE, Boampong-Konam K, Zell SC. Sociodemographic Characteristics as Predictors of Outcomes in Hepatocellular Carcinoma: A Retrospective Cohort Study. Cancer Control 2020;27:1073274820956615. [PMID: 32951450 DOI: 10.1177/1073274820956615] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology 2008;47:1058-66. [PMID: 18302296 DOI: 10.1002/hep.22223] [Cited by in Crossref: 109] [Cited by in F6Publishing: 91] [Article Influence: 7.8] [Reference Citation Analysis]
8 Aladag M, Camci C, Huang Y, Wright H, Rizvi S, Gurakar A, Stokes K, Sebastian A. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment. J Clin Gastroenterol 2005;39:923-4. [PMID: 16208125 DOI: 10.1097/01.mcg.0000180801.64575.4f] [Reference Citation Analysis]
9 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73. [PMID: 19003878 DOI: 10.1002/hep.22546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
10 Tian F, Wu JX, Yu WB. Prognostic Factors and Clinical Characteristics for Hepatocellular Carcinoma Patients with Benign Enlarged Perihepatic Lymph Nodes: a Single-Center Experience from China. J Gastrointest Surg. 2015;19:1822-1832. [PMID: 26259664 DOI: 10.1007/s11605-015-2900-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Esneault S, Hraiech N, Delabrousse E, Dillenseger JL. Graph cut liver segmentation for interstitial ultrasound therapy. Annu Int Conf IEEE Eng Med Biol Soc 2007;2007:5247-50. [PMID: 18003191 DOI: 10.1109/IEMBS.2007.4353525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Huang KW, Wu HL, Lin HL, Liang PC, Chen PJ, Chen SH, Lee HI, Su PY, Wu WH, Lee PH, Hwang LH, Chen DS. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc Natl Acad Sci USA. 2010;107:14769-14774. [PMID: 20679198 DOI: 10.1073/pnas.1009534107] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
13 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-32. [PMID: 20432259 DOI: 10.1002/hep.23594] [Cited by in Crossref: 925] [Cited by in F6Publishing: 854] [Article Influence: 77.1] [Reference Citation Analysis]
14 Lucena de la Poza JL, Turrión VS, Alvira LG, Garrido MJ, Arana RU, Sanmartin JA. Liver transplantation in the therapy of hepatocellular carcinoma: a revision of our series. Transplant Proc 2002;34:260-1. [PMID: 11959274 DOI: 10.1016/s0041-1345(01)02752-x] [Reference Citation Analysis]
15 Song TJ, Fong Y, Cho SJ, Gönen M, Hezel M, Tuorto S, Choi SY, Kim YC, Suh SO, Koo BH. Comparison of hepatocellular carcinoma in American and Asian patients by tissue array analysis. J Surg Oncol. 2012;106:84-88. [PMID: 22234941 DOI: 10.1002/jso.23036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
16 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
17 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
18 Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011;2011:565060. [PMID: 21994863 DOI: 10.4061/2011/565060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
19 Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J Gastrointest Surg. 2013;17:719-729. [PMID: 23404173 DOI: 10.1007/s11605-013-2164-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
20 Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005;41:1130-7. [PMID: 15841454 DOI: 10.1002/hep.20688] [Cited by in Crossref: 250] [Cited by in F6Publishing: 230] [Article Influence: 14.7] [Reference Citation Analysis]
21 Hernández-Guerra M, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. United European Gastroenterol J 2015;3:284-93. [PMID: 26279838 DOI: 10.1177/2050640615575971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Kuo HC, Liu WS, Wu A, Mah D, Chuang KS, Hong L, Yaparpalvi R, Guha C, Kalnicki S. Biological impact of geometric uncertainties: what margin is needed for intra-hepatic tumors? Radiat Oncol 2010;5:48. [PMID: 20525298 DOI: 10.1186/1748-717X-5-48] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zhan W, Liao X, Yu L, Tian T, Liu X, Liu J, Cai LJ, Xiao X, Xie RJ, Yang Q. Effects of blueberries on migration, invasion, proliferation, the cell cycle and apoptosis in hepatocellular carcinoma cells. Biomed Rep 2016;5:579-84. [PMID: 27882220 DOI: 10.3892/br.2016.774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Sada Y, Hou J, Richardson P, El-Serag H, Davila J. Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing. Med Care 2016;54:e9-14. [PMID: 23929403 DOI: 10.1097/MLR.0b013e3182a30373] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
25 Youn BJ, Chung JW, Son KR, Kim HC, Jae HJ, Lee JM, Song IC, Kim IO, Park JH. Diffusion-weighted MR: therapeutic evaluation after chemoembolization of VX-2 carcinoma implanted in rabbit liver. Acad Radiol 2008;15:593-600. [PMID: 18423316 DOI: 10.1016/j.acra.2007.10.022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
26 Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015;21:220-9. [PMID: 26523267 DOI: 10.3350/cmh.2015.21.3.220] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
27 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
29 Chang YC, Ho CL, Chen HH, Chang TT, Lai WW, Dai YC, Lee WY, Chow NH. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum. Br J Cancer. 2002;87:1449-1453. [PMID: 12454776 DOI: 10.1038/sj.bjc.6600649] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
30 Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518-27. [PMID: 14768006 DOI: 10.1002/hep.20053] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 5.2] [Reference Citation Analysis]
31 Ohnishi H, Sakaguchi K, Nouso K, Kobayashi Y, Nakamura S, Tanaka H, Miyake Y, Shoji B, Iwadou S, Shiratori Y. Outcome of small liver nodules detected by computed tomographic angiography in patients with hepatocellular carcinoma. Hepatol Int 2010;4:562-8. [PMID: 21063478 DOI: 10.1007/s12072-010-9190-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Hijona E, Banales JM, Hijona L, Medina JF, Arenas J, Herreros-Villanueva M, Aldazabal P, Bujanda L. Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models. Cancer Cell Int 2012;12:5. [PMID: 22353776 DOI: 10.1186/1475-2867-12-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P, Meunier P, Delwaide J, Hustinx R. Prognostic value of 18F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 2015; 21(10): 3049-3054 [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
34 Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc’h A. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057-1068. [PMID: 23613103 DOI: 10.1007/s00259-013-2395-x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 12.9] [Reference Citation Analysis]
35 De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, Buonaguro L, Marincola FM, Wang E, Buonaguro FM. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med 2009;7:85. [PMID: 19821982 DOI: 10.1186/1479-5876-7-85] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
36 Gondolesi GE, Roayaie S, Muñoz L, Kim-Schluger L, Schiano T, Fishbein TM, Emre S, Miller CM, Schwartz ME. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239:142-9. [PMID: 14745320 DOI: 10.1097/01.sla.0000109022.32391.eb] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 9.0] [Reference Citation Analysis]
37 Zhang YJ, Li H, Wu HC, Shen J, Wang L, Yu MW, Lee PH, Bernard Weinstein I, Santella RM. Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett. 2009;275:277-284. [PMID: 19081673 DOI: 10.1016/j.canlet.2008.10.042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
38 Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol. 2008;4:803-814. [PMID: 19086847 DOI: 10.2217/14796694.4.6.803] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
39 Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology 2008;47:827-35. [PMID: 18081150 DOI: 10.1002/hep.22108] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
40 Watanabe H, Kanematsu M, Kitagawa T, Suzuki Y, Kondo H, Goshima S, Kajita K, Bae KT, Hirose Y, Miotani S, Zhou X, Fujita H. MR elastography of the liver at 3 T with cine-tagging and bending energy analysis: preliminary results. Eur Radiol 2010;20:2381-9. [PMID: 20440504 DOI: 10.1007/s00330-010-1800-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
41 Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer. 2006;6:278. [PMID: 17150109 DOI: 10.1186/1471-2407-6-278] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
42 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Nakanishi Y, Shiraha H, Nishina S, Tanaka S, Matsubara M, Horiguchi S, Iwamuro M, Takaoka N, Uemura M, Kuwaki K, Hagihara H, Toshimori J, Ohnishi H, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K. Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer 2011;11:3. [PMID: 21205319 DOI: 10.1186/1471-2407-11-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
44 Schausberger E, Hufnagl K, Parzefall W, Gerner C, Kandioler-Eckersberger D, Wrba F, Klimpfinger M, Schulte-Hermann R, Grasl-Kraupp B. Inherent growth advantage of (pre)malignant hepatocytes associated with nuclear translocation of pro-transforming growth factor alpha. Br J Cancer 2004;91:1955-63. [PMID: 15534611 DOI: 10.1038/sj.bjc.6602191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
45 Huang T, Wang J, Cai YD, Yu H, Chou KC. Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS One 2012;7:e34460. [PMID: 22493692 DOI: 10.1371/journal.pone.0034460] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
46 Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237:171-179. [PMID: 12560774 DOI: 10.1097/01.sla.0000048443.71734.bf] [Cited by in Crossref: 127] [Cited by in F6Publishing: 81] [Article Influence: 6.7] [Reference Citation Analysis]
47 Lu Y, Zhu M, Li W, Lin B, Dong X, Chen Y, Xie X, Guo J, Li M. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. J Cell Mol Med. 2016;20:549-558. [PMID: 26756858 DOI: 10.1111/jcmm.12745] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 8.7] [Reference Citation Analysis]
48 Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003;237:171-179. [PMID: 12560774 DOI: 10.1097/00000658-200302000-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
49 Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13(5): 761-767 [PMID: 17278200 DOI: 10.3748/wjg.v13.i5.761] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
50 Cozzi L, Dinapoli N, Fogliata A, Hsu WC, Reggiori G, Lobefalo F, Kirienko M, Sollini M, Franceschini D, Comito T, Franzese C, Scorsetti M, Wang PM. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 2017;17:829. [PMID: 29207975 DOI: 10.1186/s12885-017-3847-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
51 Patel T, Dangell C, Maheshwari S. Impact of age on screening and surveillance for primary liver cancer. Am J Gastroenterol 2006;101:768-74. [PMID: 16494589 DOI: 10.1111/j.1572-0241.2006.00490.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014;11:e1001770. [PMID: 25536056 DOI: 10.1371/journal.pmed.1001770] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
53 Min YW, Gwak GY, Lee MW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma. World J Gastroenterol 2012; 18(21): 2654-2660 [PMID: 22690074 DOI: 10.3748/wjg.v18.i21.2654] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
54 Morin SH, Lim AK, Cobbold JF, Taylor-Robinson SD. Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions. World J Gastroenterol 2007; 13(45): 5963-5970 [DOI: 10.3748/wjg.v13.i45.5963] [Reference Citation Analysis]
55 Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. Radiology 2008;249:346-54. [PMID: 18796686 DOI: 10.1148/radiol.2483071902] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
56 Yamaoka K, Kawaoka T, Aikata H, Ando Y, Kosaka Y, Suehiro Y, Fujii Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Saeki Y, Kuroda S, Kobayashi T, Ohdan H, Miyata Y, Okada M, Chayama K. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. Intern Med 2021;60:2047-53. [PMID: 34193774 DOI: 10.2169/internalmedicine.5870-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76. [PMID: 22420979 DOI: 10.1016/j.jhep.2012.02.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Chang ET, Keegan TH, Gomez SL, Le GM, Clarke CA, So SK, Glaser SL. The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer 2007;109:2100-8. [PMID: 17385214 DOI: 10.1002/cncr.22642] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
59 Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg. 2012;36:1824-1831. [PMID: 22532309 DOI: 10.1007/s00268-012-1587-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
60 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
61 Fecht WJ Jr, Befeler AS. Hepatocellular carcinoma: updates in primary prevention. Curr Gastroenterol Rep 2004;6:37-43. [PMID: 14720452 DOI: 10.1007/s11894-004-0024-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
62 Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS, Everson GT, Reddy KR, Fair JH, Kulik LM. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007;13:122-129. [PMID: 17192908 DOI: 10.1002/lt.20995] [Cited by in Crossref: 100] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
63 Xie Y, Tian H, Xiang H. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma? Tumori 2021;107:292-303. [PMID: 32729385 DOI: 10.1177/0300891620945029] [Reference Citation Analysis]
64 Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol. 2010;23:276-283. [PMID: 19935643 DOI: 10.1038/modpathol.2009.174] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
65 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 821] [Cited by in F6Publishing: 769] [Article Influence: 41.1] [Reference Citation Analysis]
66 Li Z, Hao D, Jiao D, Zhang W, Han X. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures. Acad Radiol 2021;28 Suppl 1:S64-70. [PMID: 33060007 DOI: 10.1016/j.acra.2020.08.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
67 Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, Yang J, Yang JY. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One 2014;9:e103228. [PMID: 25133493 DOI: 10.1371/journal.pone.0103228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
68 Dong C, Yoon YH, Chen CM, Yi HY. Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs 2011;72:892-902. [PMID: 22051203 DOI: 10.15288/jsad.2011.72.892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
69 Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol 2011;21:1233-42. [DOI: 10.1007/s00330-010-2030-1] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 12.5] [Reference Citation Analysis]
70 Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, Coleman N, Alexander GJ. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005;41:722-30. [PMID: 15791620 DOI: 10.1002/hep.20644] [Cited by in Crossref: 202] [Cited by in F6Publishing: 190] [Article Influence: 11.9] [Reference Citation Analysis]
71 Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Kurzrock R, Charnsangavej C. Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver. J Comput Assist Tomogr 2012;36:388-93. [PMID: 22805665 DOI: 10.1097/RCT.0b013e318256b1e2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
72 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989-994. [PMID: 21820396 DOI: 10.1016/j.cgh.2011.07.026] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
74 Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JPA, Prasad KR. Preoperative Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor after Curative Resection for Hepatocellular Carcinoma. World J Surg 2008;32:1757-62. [DOI: 10.1007/s00268-008-9552-6] [Cited by in Crossref: 278] [Cited by in F6Publishing: 283] [Article Influence: 19.9] [Reference Citation Analysis]
75 Gou L, Wang W, Tong A, Yao Y, Zhou Y, Yi C, Yang J. Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma. J Mol Med (Berl) 2011;89:817-27. [PMID: 21475975 DOI: 10.1007/s00109-011-0753-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
76 Yang B, Zan RY, Wang SY, Li XL, Wei ML, Guo WH, You X, Li J, Liao ZY. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96. [PMID: 25889181 DOI: 10.1186/s12957-015-0516-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
77 Han TS, Ban HS, Hur K, Cho HS. The Epigenetic Regulation of HCC Metastasis. Int J Mol Sci 2018;19:E3978. [PMID: 30544763 DOI: 10.3390/ijms19123978] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
78 Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31:100-110. [PMID: 19934210 DOI: 10.1093/carcin/bgp263] [Cited by in Crossref: 484] [Cited by in F6Publishing: 404] [Article Influence: 37.2] [Reference Citation Analysis]
79 Seo JH, Kim DH, Cho E, Jun CH, Park SY, Cho SB, Park CH, Kim HS, Choi SK, Rew JS. Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea. In Vivo. 2019;33:145-154. [PMID: 30587615 DOI: 10.21873/invivo.11451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
80 Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J, Yamaoka Y, Curley SA, Ellis LM, Nagorney DM. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg. 2003;238:711-719. [PMID: 14578734 DOI: 10.1097/01.sla.0000094436.34556.ac] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
81 Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol 2017;35:3575-81. [PMID: 28872925 DOI: 10.1200/JCO.2017.73.8245] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 9.6] [Reference Citation Analysis]
82 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
83 Bharadwaj S, Gohel TD. Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2016;4:237-40. [PMID: 25563577 DOI: 10.1093/gastro/gou089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
84 Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology 2004;39:476-83. [PMID: 14768001 DOI: 10.1002/hep.20049] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 5.9] [Reference Citation Analysis]
85 Ng CS, Chandler AG, Wei W, Herron DH, Anderson EF, Kurzrock R, Charnsangavej C. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology. 2011;260:762-770. [PMID: 21788525 DOI: 10.1148/radiol.11110331] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
86 Mehta AS, Gu B, Conyers B, Ouzounov S, Wang L, Moriarty RM, Dwek RA, Block TM. alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses. Antimicrob Agents Chemother 2004;48:2085-90. [PMID: 15155204 DOI: 10.1128/AAC.48.6.2085-2090.2004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
87 Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-70. [PMID: 23280550 DOI: 10.1002/hep.26218] [Cited by in Crossref: 325] [Cited by in F6Publishing: 360] [Article Influence: 36.1] [Reference Citation Analysis]
88 Harlan LC, Parsons HM, Wiggins CL, Stevens JL, Patt YZ. Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. Liver Cancer. 2015;4:70-83. [PMID: 26020030 DOI: 10.1159/000367729] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
89 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308. [PMID: 18666317 DOI: 10.3748/wjg.v14.i27.4300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Tuttle RM, Fox JP, Ouellette JR, Hellan M. Hospital-based, acute care encounters after radiofrequency ablation of hepatic tumours. HPB (Oxford) 2014;16:845-51. [PMID: 24467271 DOI: 10.1111/hpb.12220] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:793-6. [PMID: 26171182 DOI: 10.3892/mco.2015.536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
92 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? J Hepatol. 2012;57:69-76. [PMID: 22420979 DOI: 10.1016/j.jhep.2012.02.022] [Cited by in Crossref: 276] [Cited by in F6Publishing: 302] [Article Influence: 27.6] [Reference Citation Analysis]
93 Mohsen AH; Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13. [PMID: 11302973 DOI: 10.1136/gut.48.5.707] [Cited by in Crossref: 70] [Cited by in F6Publishing: 80] [Article Influence: 3.3] [Reference Citation Analysis]
94 Rahman A, Assifi MM, Pedroso FE, Maley WR, Sola JE, Lavu H, Winter JM, Yeo CJ, Koniaris LG. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg. 2012;16:1897-1909. [PMID: 22836922 DOI: 10.1007/s11605-012-1973-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
95 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
96 Park TY, Na YC, Lee WH, Kim JH, Chang WS, Jung HH, Chang JH, Chang JW, Park YG. Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy. Brain Tumor Res Treat 2013;1:78-84. [PMID: 24904896 DOI: 10.14791/btrt.2013.1.2.78] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
97 Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, DeMatteo RP. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238:315-21; discussion 321-3. [PMID: 14501497 DOI: 10.1097/01.sla.0000086548.84705.ef] [Cited by in Crossref: 106] [Cited by in F6Publishing: 134] [Article Influence: 5.6] [Reference Citation Analysis]
98 Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32. [PMID: 18980227 DOI: 10.1002/hep.22626] [Cited by in Crossref: 189] [Cited by in F6Publishing: 165] [Article Influence: 14.5] [Reference Citation Analysis]
99 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 96] [Article Influence: 2.3] [Reference Citation Analysis]
100 Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002;36:410-7. [PMID: 12143050 DOI: 10.1053/jhep.2002.34744] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 6.1] [Reference Citation Analysis]
101 Anaparthy R, Talwalkar JA, Yin M, Roberts LR, Fidler JL, Ehman RL. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocellular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther 2011;34:83-91. [PMID: 21535445 DOI: 10.1111/j.1365-2036.2011.04673.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
102 Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012;12:16. [PMID: 22244160 DOI: 10.1186/1471-2407-12-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
103 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
104 Sakaguchi T, Suzuki S, Morita Y, Oishi K, Suzuki A, Fukumoto K, Inaba K, Nakamura S, Konno H. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today. 2010;40:638-645. [PMID: 20582515 DOI: 10.1007/s00595-009-4109-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
105 Wan P, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ, Xia Q. Living-donor or deceased-donor liver transplantation for hepatic carcinoma: A case-matched comparison. World J Gastroenterol 2014; 20(15): 4393-4400 [PMID: 24764678 DOI: 10.3748/wjg.v20.i15.4393] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
106 Wich C, Agaimy A, Strobel D, Wissniowski TT, Hartmann A, Ocker M. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World J Gastroenterol 2010; 16(28): 3592-3596 [PMID: 20653070 DOI: 10.3748/wjg.v16.i28.3592] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
107 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-9. [PMID: 15753540 DOI: 10.1136/gut.2004.052167] [Cited by in Crossref: 469] [Cited by in F6Publishing: 423] [Article Influence: 27.6] [Reference Citation Analysis]
108 Kim WR, Therneau TM, Benson JT, Kremers WK, Rosen CB, Gores GJ, Dickson ER. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology 2006;43:345-51. [PMID: 16440361 DOI: 10.1002/hep.21025] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 6.6] [Reference Citation Analysis]
109 Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506. [PMID: 16552201 DOI: 10.1097/01.sla.0000206017.29651.99] [Cited by in Crossref: 229] [Cited by in F6Publishing: 211] [Article Influence: 14.3] [Reference Citation Analysis]
110 Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3843-3849 [PMID: 25852268 DOI: 10.3748/wjg.v21.i13.3843] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
111 Duan X, Li T, Han X, Ren J, Chen P, Li H, Gong S. The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide. Oncotarget 2017;8:90905-15. [PMID: 29207612 DOI: 10.18632/oncotarget.18677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
112 Ortiz AP, Soto-Salgado M, Calo WA, Tortolero-Luna G, Pérez CM, Romero CJ, Pérez J, Figueroa-Vallés N, Suárez E. Incidence and mortality rates of selected infection-related cancers in Puerto Rico and in the United States. Infect Agent Cancer 2010;5:10. [PMID: 20470399 DOI: 10.1186/1750-9378-5-10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
113 Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic Impact of Surgical Complications and Preoperative Serum Hepatocyte Growth Factor in Hepatocellular Carcinoma Patients After Initial Hepatectomy. J Gastrointest Surg 2009;13:325-33. [DOI: 10.1007/s11605-008-0711-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
114 Bagi CM, Andresen CJ. Models of hepatocellular carcinoma and biomarker strategy. Cancers (Basel) 2010;2:1441-52. [PMID: 24281167 DOI: 10.3390/cancers2031441] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
115 Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol 2009;44:122-31. [DOI: 10.1007/s00535-008-2263-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
116 Cha DI, Lee MW, Rhim H, Choi D, Kim YS, Lim HK. Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations. Korean J Radiol 2013;14:240-7. [PMID: 23483664 DOI: 10.3348/kjr.2013.14.2.240] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
117 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 9.6] [Reference Citation Analysis]
118 Sasahira N, Tada M, Yoshida H, Tateishi R, Shiina S, Hirano K, Isayama H, Toda N, Komatsu Y, Kawabe T, Omata M. Extrahepatic biliary obstruction after percutaneous tumour ablation for hepatocellular carcinoma: aetiology and successful treatment with endoscopic papillary balloon dilatation. Gut 2005;54:698-702. [PMID: 15831919 DOI: 10.1136/gut.2003.038331] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
119 Yu L, Xu F, Gao L. Predict New Therapeutic Drugs for Hepatocellular Carcinoma Based on Gene Mutation and Expression. Front Bioeng Biotechnol 2020;8:8. [PMID: 32047745 DOI: 10.3389/fbioe.2020.00008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
120 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
121 Wang XP, Mao MJ, He ZL, Zhang L, Chi PD, Su JR, Dai SQ, Liu WL. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer 2017;8:2079-87. [PMID: 28819409 DOI: 10.7150/jca.19181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
122 Kaplan DE, Mehta R, D'Addeo K, Valderrama A, Taddei TH; Sorafenib for Hepatocellular carcinomA in VEterans (SHAVE) Study Investigators. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study. Medicine (Baltimore) 2018;97:e9757. [PMID: 29369224 DOI: 10.1097/MD.0000000000009757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int J Oncol. 2013;42:1133-1138. [PMID: 23426905 DOI: 10.3892/ijo.2013.1829] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 8.3] [Reference Citation Analysis]
124 Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med. 2016;31:242-252. [PMID: 26874512 DOI: 10.3904/kjim.2015.112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
125 Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-47. [PMID: 17393520 DOI: 10.1002/hep.21622] [Cited by in Crossref: 487] [Cited by in F6Publishing: 471] [Article Influence: 32.5] [Reference Citation Analysis]
126 Mohr L, Shankara S, Yoon SK, Krohne TU, Geissler M, Roberts B, Blum HE, Wands JR. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000;31:606-14. [PMID: 10706550 DOI: 10.1002/hep.510310310] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
127 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
128 Dugum M, Hanouneh I, McIntyre T, Pai R, Aucejo F, Eghtesad B, Zein N. Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study. Mol Clin Oncol. 2016;4:369-374. [PMID: 26998285 DOI: 10.3892/mco.2016.728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
129 Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-20. [PMID: 11358902 DOI: 10.1136/gut.48.6.816] [Cited by in Crossref: 268] [Cited by in F6Publishing: 255] [Article Influence: 12.8] [Reference Citation Analysis]
130 Kaibori M, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J, Koreeda C, Seki T, Sawada S, Okazaki K, Kwon AH. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci 2012;57:1404-12. [PMID: 22271410 DOI: 10.1007/s10620-012-2029-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
131 Esneault S, Lafon C, Dillenseger JL. Liver vessels segmentation using a hybrid geometrical moments/graph cuts method. IEEE Trans Biomed Eng 2010;57:276-83. [PMID: 19783500 DOI: 10.1109/TBME.2009.2032161] [Cited by in Crossref: 51] [Cited by in F6Publishing: 8] [Article Influence: 3.9] [Reference Citation Analysis]
132 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
133 Zhou J, Xiao YS, Tang ZY, Fan J, Wu ZQ, Zhao Y, Xue Q, Shen ZZ, Liu YK, Ye SL. Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration. J Cancer Res Clin Oncol 2005;131:547-51. [PMID: 15864645 DOI: 10.1007/s00432-005-0669-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
134 Wang PM, Hsu WC, Chung NN, Chang FL, Jang CJ, Fogliata A, Scorsetti M, Cozzi L. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol 2014;9:18. [PMID: 24410988 DOI: 10.1186/1748-717X-9-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
135 Altomonte J, Wu L, Chen L, Meseck M, Ebert O, García-Sastre A, Fallon J, Woo SL. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008;16:146-53. [PMID: 18071337 DOI: 10.1038/sj.mt.6300343] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
136 Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 2001; 7(5): 630-636 [PMID: 11819844 DOI: 10.3748/wjg.v7.i5.630] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 244] [Article Influence: 12.0] [Reference Citation Analysis]
137 Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120:3485-3493. [PMID: 25042049 DOI: 10.1002/cncr.28832] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 9.9] [Reference Citation Analysis]
138 Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-658. [PMID: 17681183 DOI: 10.1053/j.gastro.2007.05.022] [Cited by in Crossref: 1863] [Cited by in F6Publishing: 1805] [Article Influence: 124.2] [Reference Citation Analysis]
139 Li M, Yu X, Li W, Liu T, Deng G, Liu W, Liu H, Gao F. Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway. Oncotarget 2018;9:152-66. [PMID: 29416603 DOI: 10.18632/oncotarget.22077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
140 Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS, Park HJ, Song EY, Kim DG. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res 2008;14:1080-9. [PMID: 18281540 DOI: 10.1158/1078-0432.CCR-07-1615] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
141 Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 1646. [PMID: 17912593 DOI: 10.1007/s11605-007-0315-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
142 Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006;23:1417-50. [PMID: 16779701 DOI: 10.1007/s11095-006-0284-8] [Cited by in Crossref: 596] [Cited by in F6Publishing: 477] [Article Influence: 37.3] [Reference Citation Analysis]
143 Ippolito D, Inchingolo R, Grazioli L, Drago SG, Nardella M, Gatti M, Faletti R. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. World J Gastroenterol 2018;24:2413-26. [PMID: 29930464 DOI: 10.3748/wjg.v24.i23.2413] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
144 Assed C, Marchiori E, Zanetti G, Mano CM, Sarcinelli-Luz B, Vianna FG, Carvalho JF, Santos IG, Santos AA, Vianna AD. Pulmonary metastases from primary hepatocellular carcinoma in a 26-year-old patient: a case report. Cases J 2009;2:6256. [PMID: 19918566 DOI: 10.4076/1757-1626-2-6256] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
145 Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011;10:M110.004945. [PMID: 21518826 DOI: 10.1074/mcp.M110.004945] [Cited by in Crossref: 151] [Cited by in F6Publishing: 121] [Article Influence: 13.7] [Reference Citation Analysis]
146 Zhang YJ. Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma. World J Hepatol 2010; 2(3): 94-102 [PMID: 21160980 DOI: 10.4254/wjh.v2.i3.94] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
147 Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F; EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661-70; quiz 1660, 1671. [PMID: 17555459 DOI: 10.1111/j.1572-0241.2007.01337.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 6.7] [Reference Citation Analysis]
148 Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JL, Hilzenrat N, Wong P, Deschênes M. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007;21:39-45. [PMID: 17225881 DOI: 10.1155/2007/206383] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
149 Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B 2015;5:544-53. [PMID: 26713269 DOI: 10.1016/j.apsb.2015.09.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
150 Cai H, Kong W, Zhou T, Qiu Y. Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2014;93:e122. [PMID: 25396332 DOI: 10.1097/MD.0000000000000122] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
151 Hotta N, Ayada M, Okumura A, Ishikawa T, Sato K, Oohashi T, Hijikata Y, Kakumu S. Hepatocellular Carcinoma 11 and a Half Years after the Resolution of Chronic Hepatitis C Virus Infection Successfully Treated with Interferon. Case Rep Gastroenterol 2009;3:175-81. [PMID: 21103271 DOI: 10.1159/000225244] [Reference Citation Analysis]
152 Qiu SJ, Lu L, Qiao C, Wang L, Wang Z, Xiao X, Qian S, Fung JJ, Ye SL, Bonham CA. Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. J Cancer Res Clin Oncol. 2005;131:429-438. [PMID: 15818505 DOI: 10.1007/s00432-004-0616-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
153 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27. [PMID: 18821591 DOI: 10.1002/hep.22506] [Cited by in Crossref: 775] [Cited by in F6Publishing: 723] [Article Influence: 55.4] [Reference Citation Analysis]
154 Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, Larson JJ, Therneau TM, Roberts LR, Kim WR. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc 2012;87:9-16. [PMID: 22212963 DOI: 10.1016/j.mayocp.2011.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
155 Oka A, Ishimura N, Ishihara S. A New Dawn for the Use of Artificial Intelligence in Gastroenterology, Hepatology and Pancreatology. Diagnostics (Basel) 2021;11:1719. [PMID: 34574060 DOI: 10.3390/diagnostics11091719] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K. The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2010;45:459-467. [PMID: 20012107 DOI: 10.1007/s00535-009-0160-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
157 Redaelli CA, Dufour JF, Wagner M, Schilling M, Hüsler J, Krähenbühl L, Büchler MW, Reichen J. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 2002;235:77-85. [PMID: 11753045 DOI: 10.1097/00000658-200201000-00010] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 3.7] [Reference Citation Analysis]
158 Yamashita T, Kaneko S. Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. J Gastroenterol. 2014;49:1105-1110. [PMID: 24647548 DOI: 10.1007/s00535-014-0951-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
159 Jacob JR, Sterczer A, Toshkov IA, Yeager AE, Korba BE, Cote PJ, Buendia MA, Gerin JL, Tennant BC. Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors. Hepatology 2004;39:1008-16. [PMID: 15057905 DOI: 10.1002/hep.20106] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.1] [Reference Citation Analysis]
160 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.53/j.gastro.2009.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Heron V, Fortinsky KJ, Spiegle G, Hilzenrat N, Szilagyi A. Resected Hepatocellular Carcinoma in a Patient with Crohn's Disease on Azathioprine. Case Rep Gastroenterol 2016;10:50-6. [PMID: 27403102 DOI: 10.1159/000444012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
162 Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006;43:891-902. [PMID: 16628664 DOI: 10.1002/hep.21196] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
163 Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol 2004;99:2158-65. [PMID: 15554997 DOI: 10.1111/j.1572-0241.2004.40336.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
164 Mitra B, Thapa RJ, Guo H, Block TM. Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. Antiviral Res. 2018;158:185-198. [PMID: 30145242 DOI: 10.1016/j.antiviral.2018.08.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
165 Akkiz H. The Emerging Role of MicroRNAs in Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2014;4:45-50. [PMID: 29264318 DOI: 10.5005/jp-journals-10018-1095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
166 Poon RT, Fan ST, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol 2002;97:1480-8. [PMID: 12094870 DOI: 10.1111/j.1572-0241.2002.05792.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
167 Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg. 2004;8:200-207. [PMID: 15036196 DOI: 10.1016/j.gassur.2003.11.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
168 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
169 Wang L, Rasul A, Liu Z, Pan Y, Wang W, Li J, Li X. The Loss of Masculine With Declined Serum DHT Is Associated With High Risk of Hepatocellular Carcinoma in Chinese Men. Front Endocrinol (Lausanne) 2020;11:362. [PMID: 32695068 DOI: 10.3389/fendo.2020.00362] [Reference Citation Analysis]
170 Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015;38:352-60. [PMID: 25373796 DOI: 10.1007/s00270-014-1012-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
171 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 194] [Cited by in F6Publishing: 178] [Article Influence: 38.8] [Reference Citation Analysis]
172 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1002/hep.1840360706] [Cited by in Crossref: 485] [Cited by in F6Publishing: 310] [Article Influence: 24.3] [Reference Citation Analysis]
173 Xiang Y, Yang T, Pang BY, Zhu Y, Liu YN. The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int 2016;2016:7614971. [PMID: 27610139 DOI: 10.1155/2016/7614971] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
174 Marinho RT, Giria J, Moura MC. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). World J Gastroenterol 2007; 13(10): 1522-1527 [PMID: 17461443 DOI: 10.3748/wjg.v13.i10.1522] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
175 Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Zhan Q, Deng X, Chen H, Shen B, Peng C, Li H, Zhu Z. miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14. PLoS One 2014;9:e115577. [PMID: 25549355 DOI: 10.1371/journal.pone.0115577] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
176 Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. [PMID: 28694740 DOI: 10.4103/jcar.JCar_9_16] [Cited by in Crossref: 313] [Cited by in F6Publishing: 221] [Article Influence: 62.6] [Reference Citation Analysis]
177 Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76. [PMID: 15349906 DOI: 10.1002/hep.20375] [Cited by in Crossref: 651] [Cited by in F6Publishing: 577] [Article Influence: 36.2] [Reference Citation Analysis]
178 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
179 Rosen HR, Weston SJ, Im K, Yang H, Burton JR Jr, Erlich H, Klarquist J, Belle SH; Virahep-C Study Group. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007;46:350-8. [PMID: 17659573 DOI: 10.1002/hep.21714] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
180 Schmidt CM, Wang Y, Wiesenauer C. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis. J Gastrointest Surg 2003;7:1024-33. [PMID: 14675712 DOI: 10.1016/j.gassur.2003.09.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
181 Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998. [PMID: 18565886 DOI: 10.1200/jco.2007.15.9947] [Cited by in Crossref: 317] [Cited by in F6Publishing: 154] [Article Influence: 22.6] [Reference Citation Analysis]
182 Heinrichs D, Knauel M, Offermanns C, Berres ML, Nellen A, Leng L, Schmitz P, Bucala R, Trautwein C, Weber C. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A. 2011;108:17444-17449. [PMID: 21969590 DOI: 10.1073/pnas.1107023108] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 7.3] [Reference Citation Analysis]
183 Williams AA, Archer KJ. Elastic Net Constrained Stereotype Logit Model for Ordered Categorical Data. Biom Biostat Int J 2015;2:00049. [PMID: 30058001 DOI: 10.15406/bbij.2015.02.00049] [Reference Citation Analysis]
184 Lee HS, Park SY, Kim SK, Kweon YO, Tak WY, Cho CM, Jeon SW, Jung MK, Park HG, Lee DW. Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2012;18:302-308. [PMID: 23091811 DOI: 10.3350/cmh.2012.18.3.302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
185 Kawasaki Y, Yang SJ, Choi GH, Han DH, Lee JH, Iino S, Sakoda M, Ueno S, Natsugoe S, Choi JS. New scoring system for resectable hepatocellular carcinoma with a maximum tumor size of ≤5 cm based on preoperative tumor factors. HPB (Oxford) 2019;21:1393-9. [PMID: 30922846 DOI: 10.1016/j.hpb.2019.02.018] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
186 Wong K, Ozeki K, Kwong A, Patel BN, Kwo P. The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PLoS One 2018;13:e0208233. [PMID: 30592722 DOI: 10.1371/journal.pone.0208233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
187 Tran TT, Martin P. Chronic Hepatitis C. Curr Treat Options Gastroenterol. 2001;4:503-510. [PMID: 11696276 DOI: 10.1007/s11938-001-0015-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
188 Park EK, Kim HJ, Kim CY, Hur YH, Koh YS, Kim JC, Kim HJ, Kim JW, Cho CK. A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Ann Surg Treat Res 2014;87:72-80. [PMID: 25114886 DOI: 10.4174/astr.2014.87.2.72] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
189 Li Y, Di C, Li W, Cai W, Tan X, Xu L, Yang L, Lou G, Yan Y. Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis. Dig Dis Sci 2016;61:2315-27. [PMID: 27156077 DOI: 10.1007/s10620-016-4156-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
190 Cho YK, Kim JW, Kim MY, Cho HJ. Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas. Gut Liver. 2018;12:79-85. [PMID: 28798287 DOI: 10.5009/gnl17046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
191 Calama Sainz R, Tome M, Sánchez-gonzález M, Miina. J, Spanos K, Palahi M. Modelling Non-Wood Forest Products in Europe: a review. Forest Syst 2011;3:69. [DOI: 10.5424/fs/201019s-9324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol. 2006;33:S79-S83. [PMID: 17178294 DOI: 10.1053/j.seminoncol.2006.10.015.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 elSaadany S, Tepper M, Mao Y, Semenciw R, Giulivi A. An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 2002;93:443-6. [PMID: 12448868 [PMID: 12448868 DOI: 10.1007/bf03405035] [Cited by in Crossref: 19] [Article Influence: 1.0] [Reference Citation Analysis]
194 Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015;5:19-25. [PMID: 29201680 DOI: 10.5005/jp-journals-10018-1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
195 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(9): 1416-1419 [DOI: 10.11569/wcjd.v11.i9.1416] [Reference Citation Analysis]
196 Gerard B, Bleiberg H. Treatment of hepatocarcinoma. Curr Oncol Rep 2004;6:184-91. [PMID: 15066229 DOI: 10.1007/s11912-004-0048-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
197 Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022-1027. [PMID: 23299519 DOI: 10.1097/sla.0b013e31827da749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
198 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. World J Surg 2019;43:886-93. [PMID: 30361748 DOI: 10.1007/s00268-018-4829-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
199 Choi CS, Kim KH, Seo GS, Cho EY, Oh HJ, Choi SC, Kim TH, Kim HC, Roh BS. Cerebral and pulmonary embolisms after transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008; 14(30): 4834-4837 [PMID: 18720550 DOI: 10.3748/wjg.14.4834] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
200 Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52 Suppl 3:iii1-8. [PMID: 12692148 DOI: 10.1136/gut.52.suppl_3.iii1] [Cited by in Crossref: 144] [Cited by in F6Publishing: 187] [Article Influence: 7.6] [Reference Citation Analysis]
201 Khan YF, Abbas MT, El Mudathir M, Errayes M, El Hiday AH. Clinical Pattern of Cirrhotic Ascities in the State of Qatar. Qatar Medical Journal 2008;2008. [DOI: 10.5339/qmj.2008.1.16] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
202 Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48:103-9. [PMID: 11115830 DOI: 10.1136/gut.48.1.103] [Cited by in Crossref: 146] [Cited by in F6Publishing: 147] [Article Influence: 7.0] [Reference Citation Analysis]
203 Chen X, Cheng JY, Yin J. Predicting microRNA-disease associations using bipartite local models and hubness-aware regression. RNA Biol 2018;15:1192-205. [PMID: 30196756 DOI: 10.1080/15476286.2018.1517010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
204 Qiu W, Zhou B, Zou H, Liu X, Chu PG, Lopez R, Shih J, Chung C, Yen Y. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. Am J Pathol 2004;165:1689-99. [PMID: 15509538 DOI: 10.1016/s0002-9440(10)63425-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
205 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol. 2013;5:311-322. [PMID: 23805355 DOI: 10.4254/wjh.v.5.i6.311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology 2016;64:2210-8. [PMID: 27506929 DOI: 10.1002/hep.28741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
207 Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ, Orloff SL. A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. Am J Surg 2012;203:182-90. [PMID: 21679921 DOI: 10.1016/j.amjsurg.2011.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
208 Baillargeon J, Snyder N, Soloway RD, Paar D, Baillargeon G, Spaulding AC, Pollock BH, Arcari CM, Williams BA, Raimer BG. Hepatocellular carcinoma prevalence and mortality in a male state prison population. Public Health Rep 2009;124:120-6. [PMID: 19413034 DOI: 10.1177/003335490912400115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
209 Jono H, Ando Y. Midkine: a novel prognostic biomarker for cancer. Cancers (Basel) 2010;2:624-41. [PMID: 24281085 DOI: 10.3390/cancers2020624] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
210 Shinozaki K, Ebert O, Woo SL. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 2005;41:196-203. [PMID: 15619242 DOI: 10.1002/hep.20536] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
211 Méndez-sánchez N. Hepatology Highlights. Annals of Hepatology 2009;8:175-6. [DOI: 10.1016/s1665-2681(19)31762-4] [Reference Citation Analysis]
212 Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 2018;15:4465-76. [PMID: 29731831 DOI: 10.3892/etm.2018.5959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
213 Knechtle SJ. Challenging choices: liver transplantation for hepatocellular carcinoma. Ann Surg 2004;239:160-1. [PMID: 14745322 DOI: 10.1097/01.sla.0000109169.72607.50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
214 Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 2002;35:1215-24. [PMID: 11981772 DOI: 10.1053/jhep.2002.32710] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
215 Soto-Salgado M, Suárez E, Ortiz AP, Adrovet S, Marrero E, Meléndez M, Colón HM, Albizu C, Del C Santos M, Torres E, Pérez CM. Knowledge of viral hepatitis among Puerto Rican adults: implications for prevention. J Community Health 2011;36:565-73. [PMID: 21125319 DOI: 10.1007/s10900-010-9342-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
216 Shiraishi J, Sugimoto K, Moriyasu F, Kamiyama N, Doi K. Computer-aided diagnosis for the classification of focal liver lesions by use of contrast-enhanced ultrasonography. Med Phys 2008;35:1734-46. [PMID: 18561648 DOI: 10.1118/1.2900109] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
217 Mechie NC, Goralzcyk AD, Reinhardt L, Mihm S, Amanzada A. Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Res Notes 2015;8:260. [PMID: 26109044 DOI: 10.1186/s13104-015-1248-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
218 Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9. [PMID: 19065676 DOI: 10.1002/hep.22648] [Cited by in Crossref: 310] [Cited by in F6Publishing: 292] [Article Influence: 23.8] [Reference Citation Analysis]
219 Zhang YJ, Chen MS. Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma. World J Hepatol 2010; 2(4): 146-150 [PMID: 21160987 DOI: 10.4254/wjh.v2.i4.146] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
220 Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011;5:850-856. [PMID: 21484134 DOI: 10.1007/s12072-010-9249-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
221 Gao S, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R, Xiao H. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell. 2013;24:725-737. [PMID: 24332041 DOI: 10.1016/j.ccr.2013.11.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
222 Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. Am J Gastroenterol 2005;100:716-22. [PMID: 15743373 DOI: 10.1111/j.1572-0241.2005.41321.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
223 Rogers AS, Lindsey JC, Futterman DC, Zimmer B, Abdalian SE, D'Angelo LJ. Serologic examination of hepatitis B infection and immunization in HIV-positive youth and associated risks. The Pediatric AIDS Clinical Trials Group Protocol 220 Team. AIDS Patient Care STDS 2000;14:651-7. [PMID: 11119432 DOI: 10.1089/10872910050206577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
224 Azoulay D, Castaing D, Krissat J, Smail A, Hargreaves GM, Lemoine A, Emile JF, Bismuth H. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232:665-672. [PMID: 11066138 DOI: 10.1097/00000658-200011000-00008] [Cited by in Crossref: 274] [Cited by in F6Publishing: 248] [Article Influence: 12.5] [Reference Citation Analysis]
225 Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. BMC Gastroenterol 2015;15:97. [PMID: 26239732 DOI: 10.1186/s12876-015-0328-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
226 Vincent R, Sanyal A. Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players. Curr Pathobiol Rep 2014;2:109-15. [PMID: 25574453 DOI: 10.1007/s40139-014-0049-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
227 Fan X, Du H, Sun Y, Jiang J, Wang Z, Yin W, Fan K, Li H. Suppression of the Wnt signaling pathway may contribute to the inhibition of proliferation of human hepatocellular carcinoma SMMC-7721 cells by esculetin. Oncol Lett 2017;14:1731-6. [PMID: 28789402 DOI: 10.3892/ol.2017.6364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
228 Li DQ, Qiu M, Nie XM, Gui R, Huang MZ. Oxidored-nitro domain-containing protein 1 expression is associated with the progression of hepatocellular carcinoma. Oncol Lett 2016;11:3003-8. [PMID: 27123053 DOI: 10.3892/ol.2016.4362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
229 Yue PY, Wong YY, Wong KY, Tsoi YK, Leung KS. Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea. Chin Med 2013;8:21. [PMID: 24180549 DOI: 10.1186/1749-8546-8-21] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
230 Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30:387-394. [PMID: 20839030 DOI: 10.1007/s10637-010-9532-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
231 Natarajan Y, El-Serag HB. Risk Factors for Hepatocellular Carcinoma: A Historical Perspective. Clin Liver Dis (Hoboken) 2021;18:1-13. [PMID: 34745580 DOI: 10.1002/cld.1042] [Reference Citation Analysis]
232 Kim JH, Yim HJ, Lee KG, Kim SY, Jung ES, Jung YK, Seo YS, Yeon JE, Lee HS, Um SH. Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. Hepatol Int. 2011;Epub ahead of print. [PMID: 21728030 DOI: 10.1007/s12072-011-9290-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
233 Zhang Y, Ren JS, Shi JF, Li N, Wang YT, Qu C, Zhang Y, Dai M. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer. 2015;15:94. [PMID: 25879744 DOI: 10.1186/s12885-015-1113-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
234 Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol 2010; 16(32): 4061-4065 [PMID: 20731020 DOI: 10.3748/wjg.v16.i32.4061] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
235 Oberley CC, Bilger A, Drinkwater NR. Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 2015;54:959-70. [PMID: 24838184 DOI: 10.1002/mc.22165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
236 Ripoll C, Genescà J, Araujo IK, Graupera I, Augustin S, Tejedor M, Cirera I, Aracil C, Sala M, Hernandez-Guerra M, Llop E, Escorsell A, Catalina MV, Cañete N, Albillos A, Villanueva C, Abraldes JG, Bañares R, Bosch J. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology 2013;58:2079-88. [PMID: 23908019 DOI: 10.1002/hep.26629] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
237 Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon A. Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma. World J Surg 2013;37:820-8. [DOI: 10.1007/s00268-013-1902-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
238 Chok KS. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015; 7(8): 1142-1148 [PMID: 26052403 DOI: 10.4254/wjh.v7.i8.1142] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
239 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8] [Cited by in Crossref: 919] [Cited by in F6Publishing: 833] [Article Influence: 57.4] [Reference Citation Analysis]
240 Johnson NM, Qian G, Xu L, Tietze D, Marroquin-Cardona A, Robinson A, Rodriguez M, Kaufman L, Cunningham K, Wittmer J, Guerra F, Donnelly KC, Williams JH, Wang JS, Phillips TD. Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma. Sci Total Environ 2010;408:6027-31. [PMID: 20870273 DOI: 10.1016/j.scitotenv.2010.09.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
241 Tao J, Ji J, Li X, Ding N, Wu H, Liu Y, Wang XW, Calvisi DF, Song G, Chen X. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Oncotarget 2015;6:6977-88. [PMID: 25762642 DOI: 10.18632/oncotarget.3166] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
242 Yang P, Jiang Y, Pan Y, Ding X, Rhea P, Ding J, Hawke DH, Felsher D, Narla G, Lu Z, Lee RT. Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Sci Rep 2019;9:6428. [PMID: 31015523 DOI: 10.1038/s41598-019-41444-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
243 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. [PMID: 12540794 DOI: 10.1053/jhep.2003.50047] [Cited by in Crossref: 2116] [Cited by in F6Publishing: 1933] [Article Influence: 111.4] [Reference Citation Analysis]
244 Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, Naito A, Mori S, Hata K, Igarashi K. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci. 2002;47:170-176. [PMID: 11837720 DOI: 10.1023/a:1013244326874] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
245 Shah N, Cavanagh Y, Shaaban H, Stein B, Shaikh SN, Kaswala DH, Baddoura W. An unusual initial presentation of hepatocellular carcinoma as a sellar mass. J Nat Sci Biol Med 2015;6:471-4. [PMID: 26283857 DOI: 10.4103/0976-9668.160045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
246 Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:1325-1335. [PMID: 18504614 DOI: 10.1007/s00432-008-0406-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
247 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Toshima T, Taketomi A, Shirabe K, Takeishi K, Motomura T, Mano Y, Morita K, Fukuhara T, Sugimachi K, Maruoka Y, Abe K, Tajima T, Maehara Y. Solitary Asymptomatic Thyroid Metastasis from Hepatocellular Carcinoma Detected by FDG-PET/CT. Case Rep Gastroenterol 2010;4:279-85. [PMID: 21383951 DOI: 10.1159/000318858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
249 Miura N, Hasegawa J, Shiota G. Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol 2008;2:511-27. [PMID: 21892326 DOI: 10.4137/cmo.s379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
250 Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol. 2012;9:32-43. [PMID: 22025031 DOI: 10.1038/nrgastro.2011.196] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 7.4] [Reference Citation Analysis]
251 Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH, Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, Cho HS. Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget 2017;8:115444-55. [PMID: 29383172 DOI: 10.18632/oncotarget.23296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
252 Lim HK, Jeffrey GP, Ramm GA, Soekmadji C. Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Front Cell Infect Microbiol 2020;10:587628. [PMID: 33240824 DOI: 10.3389/fcimb.2020.587628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
254 Assy N, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009; 15(26): 3217-3227 [PMID: 19598296 DOI: 10.3748/wjg.15.3217] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
255 Ji XF, Fan YC, Gao S, Yang Y, Zhang JJ, Wang K. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J Gastroenterol 2014; 20(16): 4723-4729 [PMID: 24782625 DOI: 10.3748/wjg.v20.i16.4723] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
256 Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y, Kondo T. Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics 2016;13:28. [PMID: 27799868 DOI: 10.1186/s12014-016-9130-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
257 Li HG, Xie DR, Shen XM, Li HH, Zeng H, Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 2005; 11(10): 1445-1451 [PMID: 15770719 DOI: 10.3748/wjg.v11.i10.1445] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
258 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol 2014; 20(36): 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 89] [Cited by in F6Publishing: 73] [Article Influence: 11.1] [Reference Citation Analysis]
259 Lee JD, Kang WJ, Yun M. Primary Cancer of the Liver and Biliary Duct. PET Clin 2008;3:169-86. [PMID: 27156461 DOI: 10.1016/j.cpet.2008.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
260 Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709-717. [PMID: 16786357 DOI: 10.1007/s00432-006-0119-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
261 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-115; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gas20637944,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Zhang GX, Zhao ZQ, Wang HD, Hao B. Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway. World J Gastroenterol 2004; 10(2): 205-208 [PMID: 14716823 DOI: 10.3748/wjg.v10.i2.205] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
263 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83. [PMID: 12407579 DOI: 10.1053/jhep.2002.36807] [Cited by in Crossref: 37] [Cited by in F6Publishing: 135] [Article Influence: 1.9] [Reference Citation Analysis]
264 He B, Yin J, Gong S, Gu J, Xiao J, Shi W, Ding W, He Y. Bioinformatics analysis of key genes and pathways for hepatocellular carcinoma transformed from cirrhosis. Medicine (Baltimore) 2017;96:e6938. [PMID: 28640074 DOI: 10.1097/MD.0000000000006938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
265 Obulhasim G, Yasen M, Kajino K, Mogushi K, Tanaka S, Mizushima H, Tanaka H, Arii S, Hino O. Up-regulation of dbpA mRNA in hepatocellular carcinoma associated with metabolic syndrome. Hepatol Int 2013;7:215-25. [PMID: 26201636 DOI: 10.1007/s12072-012-9357-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
266 Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, Schöniger-Hekele M, Hackl F, Polli C, Rasoul-Rockenschaub S, Müller C, Wrba F, Gangl A, Ferenci P. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 2003;98:442-7. [PMID: 12591066 DOI: 10.1111/j.1572-0241.2003.07222.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
267 Han LY, Fan YC, Mu NN, Gao S, Li F, Ji XF, Dou CY, Wang K. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int J Med Sci 2014;11:164-71. [PMID: 24465162 DOI: 10.7150/ijms.6745] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
268 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 205] [Cited by in F6Publishing: 182] [Article Influence: 22.8] [Reference Citation Analysis]
269 Sohn BH, Park IY, Shin JH, Yim SY, Lee JS. Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells. Exp Mol Med 2018;50:e421. [PMID: 29303508 DOI: 10.1038/emm.2017.174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
270 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
271 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-1215; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gassur.2005.09.008] [Cited by in Crossref: 170] [Cited by in F6Publishing: 140] [Article Influence: 10.6] [Reference Citation Analysis]
272 Pomo JM, Taylor RM, Gullapalli RR. Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics. Cancer Cell Int 2016;16:44. [PMID: 27303212 DOI: 10.1186/s12935-016-0318-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
273 Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, Shomori K, Kanbe T, Oyama K, Kishimoto Y, Maruyama S. A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol. 2010;10:46. [PMID: 20482774 DOI: 10.1186/1471-230x-10-46] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
274 Vreman RA, Goodell AJ, Rodriguez LA, Porco TC, Lustig RH, Kahn JG. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model. BMJ Open 2017;7:e013543. [PMID: 28775179 DOI: 10.1136/bmjopen-2016-013543] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
275 Piasecki BA, Lewis JD, Reddy KR, Bellamy SL, Porter SB, Weinrieb RM, Stieritz DD, Chang KM. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004;40:892-899. [PMID: 15382122 DOI: 10.1002/hep.1840400419] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
276 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
277 Guy J, Yee HF Jr. Health disparities in liver disease: Time to take notice and take action. Hepatology 2009;50:309-13. [PMID: 19554619 DOI: 10.1002/hep.22942] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
278 Ito K, Yamaoka Y, Ota H, El-Zimaity H, Graham DY. Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes. Dig Dis Sci. 2008;53:2541-2549. [PMID: 18320323 DOI: 10.1007/s10620-007-0164-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
279 Jain D, Murti Y, Khan WU, Hossain R, Hossain MN, Agrawal KK, Ashraf RA, Islam MT, Janmeda P, Taheri Y, Alshehri MM, Daştan SD, Yeskaliyeva B, Kipchakbayeva A, Sharifi-Rad J, Cho WC. Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma. Oxid Med Cell Longev 2021;2021:9068850. [PMID: 34754365 DOI: 10.1155/2021/9068850] [Reference Citation Analysis]
280 Zou WY, El-Serag HB, Sada YH, Temple SL, Sansgiry S, Kanwal F, Davila JA. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci 2018;63:1173-81. [PMID: 29508165 DOI: 10.1007/s10620-018-4989-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
281 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
282 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 103] [Article Influence: 22.1] [Reference Citation Analysis]
283 Khalil A, Elfert A, Ghanem S, Helal M, Abdelsattar S, Elgedawy G, Obada M, Abdel-samiee M, El-said H. The role of metabolomics in hepatocellular carcinoma. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00085-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015;15:392. [PMID: 25957784 DOI: 10.1186/s12885-015-1373-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
285 Ng KT, Man K, Sun CK, Lee TK, Poon RT, Lo CM, Fan ST. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br J Cancer 2006;95:1050-5. [PMID: 17008870 DOI: 10.1038/sj.bjc.6603399] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 3.6] [Reference Citation Analysis]
286 Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, Russo MW, Sandler RS. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101:2128-38. [PMID: 16848807 DOI: 10.1111/j.1572-0241.2006.00723.x] [Cited by in Crossref: 440] [Cited by in F6Publishing: 393] [Article Influence: 27.5] [Reference Citation Analysis]
287 Jardon-Xicotencatl S, Díaz-Torres R, Marroquín-Cardona A, Villarreal-Barajas T, Méndez-Albores A. Detoxification of Aflatoxin-Contaminated Maize by Neutral Electrolyzed Oxidizing Water. Toxins (Basel) 2015;7:4294-314. [PMID: 26512692 DOI: 10.3390/toxins7104294] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
288 Paboriboune P, Vial T, Sitbounlang P, Bertani S, Trépo C, Dény P, Babin FX, Steenkeste N, Pineau P, Deharo E. Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients. Virol Sin 2018;33:295-303. [PMID: 29948850 DOI: 10.1007/s12250-018-0039-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
289 Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950 [PMID: 19399925 DOI: 10.3748/wjg.15.1943] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
290 Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JA, Schoenfeld PS. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569-577. [PMID: 20978844 DOI: 10.1007/s10620-010-1453-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
291 Franck M, Schütte K, Malfertheiner P, Link A. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. World J Gastroenterol 2020; 26(1): 86-96 [PMID: 31933516 DOI: 10.3748/wjg.v26.i1.86] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
292 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68. [PMID: 11106350 [PMID: 11106350 DOI: 10.1093/clinchem/46.12.2050] [Cited by in Crossref: 213] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
293 Zhou X, Popescu NC, Klein G, Imreh S. The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma. Cancer Genet Cytogenet 2007;177:6-15. [PMID: 17693185 DOI: 10.1016/j.cancergencyto.2007.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
294 Li SH, Wei W, Guo RP, Shi M, Guo ZX, Chen ZY, Xiao CZ, Cai MY, Zheng L. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Med Oncol 2013;30:696. [PMID: 23975633 DOI: 10.1007/s12032-013-0696-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
295 Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009;9:240. [PMID: 19615090 DOI: 10.1186/1471-2407-9-240] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
296 Hernaez R, El-Serag HB. Hepatocellular carcinoma surveillance: The road ahead. Hepatology 2017;65:771-3. [PMID: 27943335 DOI: 10.1002/hep.28983] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
297 Nitta H, Nakagawa S, Kaida T, Arima K, Higashi T, Taki K, Okabe H, Hayashi H, Hashimoto D, Chikamoto A, Ishiko T, Beppu T, Baba H. Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma. Surg Today 2017;47:375-84. [PMID: 27549776 DOI: 10.1007/s00595-016-1385-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
298 Abdalla MA, Haj-Ahmad Y. Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:390-403. [PMID: 23074380 DOI: 10.7150/jca.4280] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
299 Lee HW, Lee JM, Yoon JH, Kim YJ, Park JW, Park SJ, Kim SH, Yi NJ, Suh KS. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res 2018;94:74-82. [PMID: 29441336 DOI: 10.4174/astr.2018.94.2.74] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
300 Mourad YA, Khalifeh M, Taher A, Tawil A, Shamseddine A. Hepatocellular carcinoma with isolated left adrenal metastasis following liver transplantation. Ann Saudi Med 2004;24:65-7. [PMID: 15310025 DOI: 10.5144/0256-4947.2004.65] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
301 Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol 2013; 5(9): 186-194 [PMID: 24069511 DOI: 10.4251/wjgo.v5.i9.186] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
302 Pineau P, Marchio A, Nagamori S, Seki S, Tiollais P, Dejean A. Homozygous deletion scanning in hepatobiliary tumor cell lines reveals alternative pathways for liver carcinogenesis. Hepatology 2003;37:852-61. [PMID: 12668978 DOI: 10.1053/jhep.2003.50138] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
303 Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci 2018;19:E4070. [PMID: 30562917 DOI: 10.3390/ijms19124070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
304 Huang R, Yan G, Sun H, Zhang J, Song D, Kong R, Yan P, Hu P, Xie A, Wang S, Zhuang J, Yin H, Meng T, Huang Z. Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20201001. [PMID: 32627826 DOI: 10.1042/BSR20201001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
305 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Kolthammer JA, Corn DJ, Tenley N, Wu C, Tian H, Wang Y, Lee Z. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38:1248-1256. [PMID: 21344223 DOI: 10.1007/s00259-011-1743-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
307 Lingala S, Cui YY, Chen X, Ruebner BH, Qian XF, Zern MA, Wu J. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 2010;89:27-35. [PMID: 20511115 DOI: 10.1016/j.yexmp.2010.05.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
308 Zhao Y, Zhang Y, Vazirinejad Mehdiabad M, Zhou K, Chen Y, Li L, Guo J, Xu C. Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo. PLoS One 2019;14:e0223232. [PMID: 31581236 DOI: 10.1371/journal.pone.0223232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, Bruix J. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009;50:791-8. [PMID: 19610049 DOI: 10.1002/hep.23071] [Cited by in Crossref: 211] [Cited by in F6Publishing: 225] [Article Influence: 16.2] [Reference Citation Analysis]
310 Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513-521. [PMID: 17653645 DOI: 10.1007/s00535-007-2064-6] [Cited by in Crossref: 129] [Cited by in F6Publishing: 114] [Article Influence: 8.6] [Reference Citation Analysis]
311 Vlaisavljevich E, Kim Y, Allen S, Owens G, Pelletier S, Cain C, Ives K, Xu Z. Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model. Ultrasound Med Biol 2013;39:1398-409. [PMID: 23683406 DOI: 10.1016/j.ultrasmedbio.2013.02.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
312 Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg. 2014;38:490-496. [PMID: 24132826 DOI: 10.1007/s00268-013-2290-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 6.4] [Reference Citation Analysis]
313 Lee MJ, Xu DY, Li H, Yu GR, Leem SH, Chu IS, Kim IH, Kim DG. Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma. Exp Mol Med 2012;44:214-24. [PMID: 22192927 DOI: 10.3858/emm.2012.44.3.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
314 Morin SH, Lim AK, Cobbold JF, Taylor-Robinson SD. Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions. World J Gastroenterol 2007;13:5963-70. [PMID: 18023084 DOI: 10.3748/wjg.v13.45.5963] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
315 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-3491471-2407-8-349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
317 Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant 2016; 6(2): 306-313 [PMID: 27358775 DOI: 10.5500/wjt.v6.i2.306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
318 Luna LE, Kwo PY, Roberts LR, Mettler TA, Gansen DN, Andrews JC, Wiseman GA, Misra VL. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol 2009;6:679-83. [PMID: 19881519 DOI: 10.1038/nrgastro.2009.165] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
319 Han Q, Deng H, Fan X, Wang X, Zhang X, Zhang K, Li N, Lv Y, Liu Z. Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1367-73. [PMID: 34805015 DOI: 10.2147/JHC.S337936] [Reference Citation Analysis]
320 Dusheiko G, Barnes E, Webster G, Whalley S. The science, economics, and effectiveness of combination therapy for hepatitis C. Gut 2000;47:159-61. [PMID: 10896900 DOI: 10.1136/gut.47.2.159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
321 Göbel T, Vorderwülbecke S, Hauck K, Fey H, Häussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006; 12(47): 7604-7612 [PMID: 17171788 DOI: 10.3748/wjg.v12.i47.7604] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
322 Bell R, Pandanaboyana S, Lodge JPA, Prasad KR, Jones R, Hidalgo E. Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B). Langenbecks Arch Surg. 2017;402:575-583. [PMID: 27456677 DOI: 10.1007/s00423-016-1475-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
323 Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321-328. [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
325 Deng H, Fan X, Wang X, Zeng L, Zhang K, Zhang X, Li N, Han Q, Lv Y, Liu Z. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection. Sci Rep 2020;10:20276. [PMID: 33219288 DOI: 10.1038/s41598-020-77332-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, Yashima K, Kishimoto Y, Nakai Y, Miura T, Ito H, Murawaki Y, Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2'-deoxyguanosine formation. Hepatology 2002;35:1125-33. [PMID: 11981762 DOI: 10.1053/jhep.2002.33066] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.4] [Reference Citation Analysis]
327 Ling YH, Chen JW, Wen SH, Huang CY, Li P, Lu LH, Mei J, Li SH, Wei W, Cai MY, Guo RP. Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. BMC Cancer 2020;20:607. [PMID: 32600297 DOI: 10.1186/s12885-020-07097-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
328 Peveling-Oberhag J, Seiz A, Döring C, Hartmann S, Köberle V, Liese J, Zeuzem S, Hansmann ML, Piiper A. MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol 2014;7:672-80. [PMID: 25500075 DOI: 10.1016/j.tranon.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
329 Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014; 20(31): 10960-10968 [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
330 Zhang YJ, Wu HC, Yazici H, Yu MW, Lee PH, Santella RM. Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B1 exposure. World J Hepatol 2012; 4(5): 169-175 [DOI: 10.4254/wjh.v4.i5.169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
331 Li JK, Liu XH, Cui H, Xie XH. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol 2020;12:15-22. [PMID: 31814972 DOI: 10.3892/mco.2019.1941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
332 Zhou ZR, Liu M, Lu HR, Li YF, Liang SX, Zhang CY. Validation of different staging systems for hepatocellular carcinoma in a cohort of 249 patients undergoing radiotherapy. Oncotarget 2017;8:46523-31. [PMID: 28147327 DOI: 10.18632/oncotarget.14881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
333 Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, Haviland D, Shia J, D'Angelica M, Fong Y, DeMatteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009;20:1589-95. [PMID: 19491285 DOI: 10.1093/annonc/mdp029] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 8.7] [Reference Citation Analysis]
334 Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
335 Su L, Zhou T, Zhang Z, Zhang X, Zhi X, Li C, Wang Q, Jia C, Shi W, Yue Y, Gao Y, Cheng B. Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: a retrospective study. BMC Cancer 2016;16:424. [PMID: 27387757 DOI: 10.1186/s12885-016-2420-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
336 Daskalow K, Pfander D, Weichert W, Rohwer N, Thelen A, Neuhaus P, Jonas S, Wiedenmann B, Benckert C, Cramer T. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009;132:21-31. [PMID: 19350262 DOI: 10.1007/s00418-009-0590-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
337 Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, Pedrosa I, Khatri G, Yakoo T, Meyer JJ. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21:1287-1295. [PMID: 24318095 DOI: 10.1245/s10434-013-3413-8] [Cited by in Crossref: 102] [Cited by in F6Publishing: 82] [Article Influence: 11.3] [Reference Citation Analysis]
338 Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2018;18:138. [PMID: 30180810 DOI: 10.1186/s12876-018-0849-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
339 Tenley N, Corn DJ, Yuan L, Lee Z. The effect of fasting on PET Imaging of Hepatocellular Carcinoma. J Cancer Ther. 2013;4:561-567. [PMID: 24683497 DOI: 10.4236/jct.2013.42071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
340 Lake-Bakaar G, Ahmed M, Evenson A, Bonder A, Faintuch S, Sundaram V. Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. Liver Cancer 2014;3:428-38. [PMID: 26280004 DOI: 10.1159/000343871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
341 Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 2011;6:e16435. [PMID: 21298008 DOI: 10.1371/journal.pone.0016435] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 8.2] [Reference Citation Analysis]
342 Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract. 2011;2011:595627. [PMID: 22191028 DOI: 10.1155/2011/595627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
343 Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562-1569. [PMID: 11029989 DOI: 10.2105/ajph.90.10.1562] [Cited by in Crossref: 409] [Cited by in F6Publishing: 130] [Article Influence: 18.6] [Reference Citation Analysis]
344 Wang PM, Hsu WC, Chung NN, Chang FL, Fogliata A, Cozzi L. Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile from a retrospective analysis of 138 patients. Radiat Oncol 2012;7:207. [PMID: 23216929 DOI: 10.1186/1748-717X-7-207] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
345 Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, Ortiz Pedraza Y, Cigliano A, Pascale RM, Calvisi DF, Liu Y, Chen X. Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. Cancer Med 2018;7:6170-81. [PMID: 30370649 DOI: 10.1002/cam4.1777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
346 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
347 Lou CY, Feng YM, Qian AR, Li Y, Tang H, Shang P, Chen ZN. Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol 2004; 10(10): 1462-1465 [PMID: 15133854 DOI: 10.3748/wjg.v10.i10.1462] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
348 Cai MY, Hou JH, Rao HL, Luo RZ, Li M, Pei XQ, Lin MC, Guan XY, Kung HF, Zeng YX. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med. 2011;17:12-20. [PMID: 20844838 DOI: 10.2119/molmed.2010.00103] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
349 Zeng FY, Zhao KL, Lin LZ, Deng Y, Qin S, Ye JR, Huang ZQ. Gan-Qing-Ning Formula Inhibits the Growth of Hepatocellular Carcinoma by Promoting Apoptosis and Inhibiting Angiogenesis in H22 Tumor-Bearing Mice. Evid Based Complement Alternat Med 2020;2020:6376912. [PMID: 32831873 DOI: 10.1155/2020/6376912] [Reference Citation Analysis]
350 Machida K. Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus. Drug Deliv Transl Res 2013;3:152-64. [PMID: 25787983 DOI: 10.1007/s13346-012-0115-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
351 Cheng JT, Tan NE, Volk ML. Utility of positron emission tomography-computed tomography scan in detecting residual hepatocellular carcinoma post treatment: Series of case reports. World J Gastrointest Oncol 2020; 12(3): 358-364 [PMID: 32206185 DOI: 10.4251/wjgo.v12.i3.358] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
352 Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology 2010;51:1401-9. [PMID: 20054870 DOI: 10.1002/hep.23488] [Cited by in Crossref: 101] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
353 Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91. [PMID: 11286466 DOI: 10.1054/bjoc.2000.1716] [Cited by in Crossref: 233] [Cited by in F6Publishing: 211] [Article Influence: 11.1] [Reference Citation Analysis]
354 Choi J, Roberts LR. Statins and metformin for chemoprevention of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;8:48-52. [PMID: 31041062 DOI: 10.1002/cld.568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
355 Mendiratta-Lala M, Park H, Kolicaj N, Mendiratta V, Bassi D. Small intrahepatic peripheral cholangiocarcinomas as mimics of hepatocellular carcinoma in multiphasic CT. Abdom Radiol (NY) 2017;42:171-8. [PMID: 27590067 DOI: 10.1007/s00261-016-0840-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
356 Mamori S, Nagatsuma K, Matsuura T, Ohkawa K, Hano H, Fukunaga M, Matsushima M, Masui Y, Fushiya N, Onoda H, Searashi Y, Takagi I, Tagiri H. Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples. World J Gastroenterol 2007; 13(21): 2913-2917 [PMID: 17589939 DOI: 10.3748/wjg.v13.i21.2913] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
357 Dandri M, Burda MR, Bürkle A, Zuckerman DM, Will H, Rogler CE, Greten H, Petersen J. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 2002;35:217-23. [PMID: 11786979 DOI: 10.1053/jhep.2002.30203] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 3.7] [Reference Citation Analysis]
358 Shah TU, Semelka RC, Pamuklar E, Firat Z, Gerber RD, Shrestha R, Russo MW. The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am J Gastroenterol 2006;101:533-40. [PMID: 16542290 DOI: 10.1111/j.1572-0241.2006.00450.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
359 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
360 Salem N, Kuang Y, Corn D, Erokwu B, Kolthammer JA, Tian H, Wu C, Wang F, Wang Y, Lee Z. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol. 2011;13:140-151. [PMID: 20401538 DOI: 10.1007/s11307-010-0308-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
361 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
362 Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol. 2011;6:121. [PMID: 22151825 DOI: 10.1186/1746-1596-6-121] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
363 Li D, Zeng Z. Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis. Biosci Rep 2019;39:BSR20191815. [PMID: 31320544 DOI: 10.1042/BSR20191815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
364 Mamori S, Asakura T, Ohkawa K, Tajiri H. Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol 2007; 13(40): 5306-5311 [PMID: 17879398 DOI: 10.3748/wjg.v13.i40.5306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
365 Sun VC, Sarna L. Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs. 2008;12:759-766. [PMID: 18842532 DOI: 10.1188/08.cjon.759-766] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
366 Al-Qubaisi M, Rozita R, Yeap SK, Omar AR, Ali AM, Alitheen NB. Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. Molecules 2011;16:2944-59. [PMID: 21471934 DOI: 10.3390/molecules16042944] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 7.8] [Reference Citation Analysis]
367 Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8. [PMID: 10613728 DOI: 10.1002/hep.510310111] [Cited by in Crossref: 187] [Cited by in F6Publishing: 163] [Article Influence: 8.5] [Reference Citation Analysis]
368 Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford). 2010;12:625-636. [PMID: 20961371 DOI: 10.1111/j.1477-2574.2010.00207.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
369 Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, Kukita K, Hirata K. Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg. 2011;15:1433-1439. [PMID: 21607795 DOI: 10.1007/s11605-011-1566-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
370 Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg. 2004;28:376-381. [PMID: 15022021 DOI: 10.1007/s00268-003-7308-x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 108] [Article Influence: 5.8] [Reference Citation Analysis]
371 Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006;44:1518-27. [PMID: 17133456 DOI: 10.1002/hep.21408] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 6.8] [Reference Citation Analysis]
372 Poddar N, Avezbakiyev B, He Z, Jiang M, Gohari A, Wang JC. Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis. J Gastrointest Cancer. 2012;43:486-489. [PMID: 21190093 DOI: 10.1007/s12029-010-9235-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
373 Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, Jäkel O, Haberer T, Debus J. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011;11:67. [PMID: 21314962 DOI: 10.1186/1471-2407-11-67] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
374 Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging. 2005;5:20-24. [PMID: 16154814 DOI: 10.1102/1470-7330.2005.0005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
375 Li C, Zhang F, Zhang W, Zhang L, Huang Z, Wu P. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1633-1640. [PMID: 20865361 DOI: 10.1007/s00432-010-0821-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
376 Chanyaputhipong J, Low SC, Chow PK. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol. 2011;2011:489342. [PMID: 21994860 DOI: 10.4061/2011/489342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
377 Morin SH, Lim AK, Cobbold JF, Taylor-Robinson SD. Use of second generation contrast-enhanced ultrasound in the assessment of focal liver lesions. World J Gastroenterol. 2007;13:5963-5970. [PMID: 18023084 DOI: dx.doi.org/10.3748/wjg.13.5963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
378 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
379 Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5. [PMID: 10655254 DOI: 10.1002/hep.510310211] [Cited by in Crossref: 292] [Cited by in F6Publishing: 277] [Article Influence: 13.3] [Reference Citation Analysis]
380 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget 2016;7:64400-9. [PMID: 27462865 DOI: 10.18632/oncotarget.10794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
381 Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF, Kumar AP, Senapati P, Behera AK, Hui KM, Basha J, Natesh N, Luk JM, Kundu TK. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 2014;13:66. [PMID: 24655440 DOI: 10.1186/1476-4598-13-66] [Cited by in Crossref: 115] [Cited by in F6Publishing: 112] [Article Influence: 14.4] [Reference Citation Analysis]
382 Chang ET, Yang J, Alfaro-Velcamp T, So SK, Glaser SL, Gomez SL. Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev. 2010;19:3106-3118. [PMID: 20940276 DOI: 10.1158/1055-9965.epi-10-0863] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
383 Kajihara J, Tomimaru Y, Eguchi H, Yamada D, Wada H, Tomokuni A, Asaoka T, Kawamoto K, Marubashi S, Nagano H, Umeshita K, Doki Y, Mori M. The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. Dig Dis Sci 2016;61:1572-81. [PMID: 26725068 DOI: 10.1007/s10620-015-4018-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
384 Perumalswami PV, Schiano TD. The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci 2011;56:1266-81. [PMID: 21416246 DOI: 10.1007/s10620-011-1619-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
385 Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8853-8861 [PMID: 27833376 DOI: 10.3748/wjg.v22.i40.8853] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
386 Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466-473. [PMID: 19188315 DOI: 10.1148/radiol.2502072222] [Cited by in Crossref: 144] [Cited by in F6Publishing: 137] [Article Influence: 11.1] [Reference Citation Analysis]
387 Bzeizi KI, Arabi M, Jamshidi N, Albenmousa A, Sanai FM, Al-Hamoudi W, Alghamdi S, Broering D, Alqahtani SA. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:6172. [PMID: 34944792 DOI: 10.3390/cancers13246172] [Reference Citation Analysis]
388 West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94:1751-1758. [PMID: 16736026 DOI: 10.1038/sj.bjc.6603127] [Cited by in Crossref: 167] [Cited by in F6Publishing: 157] [Article Influence: 10.4] [Reference Citation Analysis]
389 Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang N, Qiu Y, Lu J. Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling. Mol Cell Biochem. 2013;381:139-144. [PMID: 23756716 DOI: 10.1007/s11010-013-1695-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
390 Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2008;2:779-88. [PMID: 19707458 DOI: 10.2147/btt.s3410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.3] [Reference Citation Analysis]
391 Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006;33:344-52. [PMID: 16333675 DOI: 10.1007/s00259-005-1954-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
392 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
393 Thomas R, Thomas RS, Auerbach SS, Portier CJ. Biological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat species. PLoS One 2013;8:e63308. [PMID: 23737943 DOI: 10.1371/journal.pone.0063308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
394 Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Compagnon P, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouillères O, Cherqui D, Duvoux C. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World J Gastroenterol 2006; 12(45): 7319-7325 [PMID: 17143948 DOI: 10.3748/wjg.v12.i45.7319] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
395 Hao XS, Chen KX, Wang PP, Rohan T. Changes in survival patterns in urban Chinese patients with liver cancer. World J Gastroenterol 2003; 9(6): 1212-1215 [PMID: 12800226 DOI: 10.3748/wjg.v9.i6.1212] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
396 Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86. [PMID: 11923602 DOI: 10.1097/00000658-200204000-00004] [Cited by in Crossref: 300] [Cited by in F6Publishing: 283] [Article Influence: 15.0] [Reference Citation Analysis]
397 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
398 Kim DY, Kwon DS, Salem R, Ma CK, Abouljoud MS. Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. J Gastrointest Surg. 2006;10:413-416. [PMID: 16504888 DOI: 10.1016/j.gassur.2005.06.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
399 Xu W, Huang JJ, Cheung PC. Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One 2012;7:e34406. [PMID: 22470568 DOI: 10.1371/journal.pone.0034406] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
400 Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-21. [PMID: 12717392 DOI: 10.1053/jhep.2003.50195] [Cited by in Crossref: 280] [Cited by in F6Publishing: 248] [Article Influence: 14.7] [Reference Citation Analysis]
401 Tezuka M, Hayashi K, Okada Y, Irie T, Ina H. Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients. Dig Dis Sci. 2009;54:661-669. [PMID: 18649138 DOI: 10.1007/s10620-008-0388-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
402 Xue KS, Tang L, Shen CL, Pollock BH, Guerra F, Phillips TD, Wang JS. Increase in aflatoxin exposure in two populations residing in East and West Texas, United States. Int J Hyg Environ Health 2021;231:113662. [PMID: 33197706 DOI: 10.1016/j.ijheh.2020.113662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Abara WE, Spradling P, Zhong Y, Moorman A, Teshale EH, Rupp L, Gordon SC, Schmidt M, Boscarino JA, Daida YG, Holmberg SD; CHeCS Investigators. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis. J Gastrointest Cancer 2020;51:461-8. [PMID: 31124041 DOI: 10.1007/s12029-019-00255-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, Sebastiani G, Palù G, Alberti A. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009;50:1038-44. [PMID: 19676127 DOI: 10.1002/hep.23111] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
405 Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther 2008;25:1089-104. [PMID: 18972075 DOI: 10.1007/s12325-008-0113-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
406 Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC, Singal AG. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol 2012;10:1284-90. [PMID: 22902759 DOI: 10.1016/j.cgh.2012.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
407 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed. 2014;26:172-176. [PMID: 25126010 DOI: 10.5455/msm.2014.26.172-176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
408 Shimohira M, Ogino H, Kawai T, Kushita A, Watanabe M, Kawaguchi T, Kurono K, Shibamoto Y. Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma. Br J Radiol 2011;84:184-7. [PMID: 21257838 DOI: 10.1259/bjr/26974088] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
409 Qiu W, David D, Zhou B, Chu PG, Zhang B, Wu M, Xiao J, Han T, Zhu Z, Wang T. Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol. 2003;162:1961-1974. [PMID: 12759252 DOI: 10.1016/s0002-9440(10)64329-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
410 Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-8. [PMID: 15185312 DOI: 10.1002/hep.20212] [Cited by in Crossref: 212] [Cited by in F6Publishing: 183] [Article Influence: 11.8] [Reference Citation Analysis]
411 Robinson MK, Weiner LM, Adams GP. Improving mono-clonal antibodies for cancer therapy. Drug Development Res. 2004;61:172-187. [PMID: 11819809 DOI: 10.1002/ddr.10345] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
412 Ait-Oudhia S, Mager DE, Pokuri V, Tomaszewski G, Groman A, Zagst P, Fetterly G, Iyer R. Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. CPT Pharmacometrics Syst Pharmacol 2016;5:297-304. [PMID: 27300260 DOI: 10.1002/psp4.12084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
413 Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L, Zheng X. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009;49:1194-202. [PMID: 19133651 DOI: 10.1002/hep.22757] [Cited by in Crossref: 129] [Cited by in F6Publishing: 127] [Article Influence: 9.9] [Reference Citation Analysis]
414 Cho YK, Wook Chung J, Kim Y, Je Cho H, Hyun Yang S. Radiofrequency ablation of high-grade dysplastic nodules. Hepatology 2011;54:2005-11. [PMID: 21809357 DOI: 10.1002/hep.24589] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
415 Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer. 2018;18:715. [PMID: 29976149 DOI: 10.1186/s12885-018-4636-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
416 Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003;7:1082-1088. [PMID: 14675719 DOI: 10.1097/00000658-200205000-00015] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 7.6] [Reference Citation Analysis]
417 Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, Abdel-Hamid M, Gouda I, Ezzat S, Kyselova Z. Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res. 2009;15:1808-1813. [PMID: 19223512 DOI: 10.1158/1078-0432.ccr-07-5261] [Cited by in Crossref: 108] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
418 Fathi F, Sanei B, Ganjalikhani Hakemi M, Saidi RF, Rezaei A. Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:5593655. [PMID: 33987145 DOI: 10.1155/2021/5593655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
419 Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci. 2012;57:1122-1129. [PMID: 22451120 DOI: 10.1007/s10620-012-2136-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
420 Goldman R, Ressom HW, Abdel-Hamid M, Goldman L, Wang A, Varghese RS, An Y, Loffredo CA, Drake SK, Eissa SA. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007;28:2149-2153. [PMID: 17724376 DOI: 10.1093/carcin/bgm177] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
421 Ballem N, Berber E, Pitt T, Siperstein A. Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. HPB (Oxford) 2008;10:315-20. [PMID: 18982145 DOI: 10.1080/13651820802247102] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
422 Zhao H, Zhu P, Han T, Ye Q, Xu C, Wu L, Liu F, Yin W, Li Z, Guo Y. Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis B, hepatitis C and alcoholic liver disease. J Clin Lab Anal 2020;34:e23075. [PMID: 31659795 DOI: 10.1002/jcla.23075] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
423 Ueda H, Fukuchi H, Tanaka C. Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol Lett. 2012;3:259-263. [PMID: 22740891 DOI: 10.3892/ol.2011.469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
424 Siddiqui FA, Ehrinpreis MN, Janisse J, Dhar R, May E, Mutchnick MG. Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int 2008;2:376-81. [PMID: 19669268 DOI: 10.1007/s12072-008-9086-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
425 Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL. Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620. [PMID: 21062497 DOI: 10.1186/1471-2407-10-620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
426 Reis J, Butani D. Tumor Ablation. Ultrasound Clinics 2013;8:171-83. [DOI: 10.1016/j.cult.2012.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
427 Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44 Suppl 19:96-101. [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6] [Cited by in Crossref: 142] [Cited by in F6Publishing: 137] [Article Influence: 10.9] [Reference Citation Analysis]
428 Sotiropoulos GC, Spartalis E, Machairas N, Paul A, Malagó M, Neuhäuser M. Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison. Ann Gastroenterol 2018;31:722-7. [PMID: 30386123 DOI: 10.20524/aog.2018.0301] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
429 Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, Wang TC, Schmidt EV. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci USA. 2001;98:9847-9852. [PMID: 11493707 DOI: 10.1073/pnas.171319698] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 2.5] [Reference Citation Analysis]
430 Kim YJ, Jang BK, Kim ES, Chung WJ, Park KS, Cho KB, Hwang JS. Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years. J Korean Med Sci. 2012;27:1147-1154. [PMID: 23091310 DOI: 10.3346/jkms.2012.27.10.1147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
431 Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12:218-225. [PMID: 20231127 DOI: 10.1007/s12094-010-0492-x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 169] [Article Influence: 16.3] [Reference Citation Analysis]
432 Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008;300:2371-8. [PMID: 19033587 DOI: 10.1001/jama.2008.720] [Cited by in Crossref: 218] [Cited by in F6Publishing: 199] [Article Influence: 15.6] [Reference Citation Analysis]
433 Sharma B, Srinivasan R, Chawla YK, Kapil S, Saini N, Singla B, Chakraborthy A, Kalra N, Duseja A, Dhiman RK. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int. 2010;4:569-576. [PMID: 21063479 DOI: 10.1007/s12072-010-9186-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
434 Massarweh NN, Park JO, Farjah F, Yeung RS, Symons RG, Vaughan TL, Baldwin LM, Flum DR. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2010;210:441-448. [PMID: 20347736 DOI: 10.1016/j.jamcollsurg.2009.12.026] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
435 Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1121-3. [PMID: 18695130 DOI: 10.1093/jnci/djn261] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
436 Jingting J, Changping W, Ning X, yibei Z, Jun W, Mei J, Bin X, Peter NE, Xueguan Z. Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. J Clin Lab Anal 2009;23:213-8. [PMID: 19623644 DOI: 10.1002/jcla.20321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
437 Yao P, Morris DL. Radiofrequency ablation-assisted liver resection: review of the literature and our experience. HPB (Oxford). 2006;8:248-254. [PMID: 18333135 DOI: 10.1080/13651820600703272] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
438 Goode JA, Matson MB. Embolisation of cancer: what is the evidence? Cancer Imaging 2004;4:133-41. [PMID: 18250022 DOI: 10.1102/1470-7330.2004.0021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
439 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 221] [Cited by in F6Publishing: 179] [Article Influence: 73.7] [Reference Citation Analysis]
440 Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17-30. [PMID: 19669276 DOI: 10.1007/s12072-007-9038-x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 8.7] [Reference Citation Analysis]
441 Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, Matthaeis ND, Grieco A, Landolfi R, Rapaccini GL. Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2011; 17(26): 3126-3132 [PMID: 21912455 DOI: 10.3748/wjg.v17.i26.3126] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
442 Tang ZY. Hepatocellular Carcinoma-Cause, Treatment and Metastasis. World J Gastroenterol 2001; 7(4): 445-454 [PMID: 11819809 DOI: 10.3748/wjg.v7.i4.445] [Cited by in CrossRef: 287] [Cited by in F6Publishing: 300] [Article Influence: 13.7] [Reference Citation Analysis]
443 Garofalo M, Croce CM. MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat. 2013;16:47-59. [PMID: 23757365 DOI: 10.1016/j.drup.2013.05.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 11.1] [Reference Citation Analysis]
444 Huang JW, Hernandez-Alejandro R, Croome KP, Yan LN, Wu H, Chen ZY, Prasoon P, Zeng Y. Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations. World J Gastroenterol 2011; 17(1): 123-129 [PMID: 21218093 DOI: 10.3748/wjg.v17.i1.123] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
445 Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33:241-246. [PMID: 25318437 DOI: 10.1007/s10637-014-0169-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
446 Finn RS. Drug therapy: sorafenib. Hepatology 2010;51:1843-9. [PMID: 20432260 DOI: 10.1002/hep.23676] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
447 Zhu D, Fang C, Yang Z, Ren Y, Yang F, Zheng S, Jiang M, Miao X, Liu D, Chen B, Yao X, Chen Y. Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway. Cell Prolif 2022;:e13241. [PMID: 35504605 DOI: 10.1111/cpr.13241] [Reference Citation Analysis]
448 Cormier J, Thomas K, Chari R, Pinson C. Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2006;10:761-80. [DOI: 10.1016/j.gassur.2005.10.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
449 Yuan JM, Grouls M, Carmella SG, Wang R, Heskin A, Jiang Y, Tan YT, Adams-Haduch J, Gao YT, Hecht SS. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Carcinogenesis 2019;40:989-97. [PMID: 30615102 DOI: 10.1093/carcin/bgy180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
450 Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K, Koike N, Shigematsu N. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol. 2010;83:1063-1071. [PMID: 21088090 DOI: 10.1259/bjr/74105551] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
451 Dwek MV, Rawlings SL. Current perspectives in cancer proteomics. Mol Biotechnol. 2002;22:139-152. [PMID: 12405262 DOI: 10.1385/mb: 22: 2: 139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, Liu GJ, Lu MD. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011;15:2165-2171. [PMID: 21972056 DOI: 10.1007/s11605-011-1716-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
453 Dorfman JD, Schulick R, Choti MA, Geschwind JFH, Kamel I, Torbenson M, Thuluvath PJ. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol 2007; 13(5): 781-784 [PMID: 17278203 DOI: 10.3748/wjg.v13.i5.781] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
454 Galun E, Eren R, Safadi R, Ashour Y, Terrault N, Keeffe EB, Matot E, Mizrachi S, Terkieltaub D, Zohar M, Lubin I, Gopher J, Shouval D, Dagan S. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology 2002;35:673-9. [PMID: 11870383 DOI: 10.1053/jhep.2002.31867] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 3.2] [Reference Citation Analysis]
455 Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D’Amelio A, Philip R, Mehta AS, Block TM. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem. 2008;104:136-149. [PMID: 18004786 DOI: 10.1002/jcb.21610] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
456 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI, Lee SD. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2013;7:645-54. [PMID: 26201797 DOI: 10.1007/s12072-012-9375-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
457 Nitta H, Beppu T, Imai K, Hayashi H, Chikamoto A, Baba H. Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg. 2013;37:1034-1042. [PMID: 23435678 DOI: 10.1007/s00268-013-1957-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
458 Yeh ML, Huang CI, Huang CF, Hsieh MY, Lin ZY, Huang JF, Dai CY, Yu ML, Chen SC, Chuang WL. The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. PLoS One 2017;12:e0184878. [PMID: 28957337 DOI: 10.1371/journal.pone.0184878] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
459 Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16(29): 3603-3615 [PMID: 20677332 DOI: 10.3748/wjg.v16.i29.3603] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 103] [Article Influence: 9.3] [Reference Citation Analysis]
460 Mao M, Wang X, Song Y, Sheng H, Han R, Lin W, Dai S. Novel Prognostic Scores Based on Plasma Prothrombin Time and Fibrinogen Levels in Patients With AFP-Negative Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820915520. [PMID: 32216575 DOI: 10.1177/1073274820915520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
461 Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010;12:186-92. [PMID: 20425078 DOI: 10.1007/s11912-010-0094-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
462 Heathcote EJ. Clinical trials and their translation in hepatology: past, present, and future. Hepatology 2012;56:399-410. [PMID: 22213049 DOI: 10.1002/hep.25557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
463 Toyoda H, Kumada T, Osaki Y, Tada T, Kaneoka Y, Maeda A. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci 2012;103:921-5. [PMID: 22320249 DOI: 10.1111/j.1349-7006.2012.02232.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
464 Machida K, Tahara SM. Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers (Basel) 2022;14:2381. [PMID: 35625986 DOI: 10.3390/cancers14102381] [Reference Citation Analysis]
465 Khan R, Zahid S, Wan YJ, Forster J, Karim AB, Nawabi AM, Azhar A, Rahman MA, Ahmed N. Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. Clin Proteomics 2013;10:6. [PMID: 23724895 DOI: 10.1186/1559-0275-10-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
466 Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013;57:1838-46. [PMID: 23299860 DOI: 10.1002/hep.26223] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
467 Liu S, Yu M, He Y, Xiao L, Wang F, Song C, Sun S, Ling C, Xu Z. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 2008;47:1964-73. [PMID: 18506888 DOI: 10.1002/hep.22240] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 9.2] [Reference Citation Analysis]
468 Kirikoshi H, Saito S, Ueno N, Suzuki K, Takahashi H, Yoneda M, Fujita K, Nakajima A. Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy. J Med Ultrason (2001) 2010;37:137-41. [PMID: 27278013 DOI: 10.1007/s10396-010-0259-6] [Reference Citation Analysis]
469 Wee CW, Kim K, Chie EK, Yu SJ, Kim YJ, Yoon JH. Prognostic stratification and nomogram for survival prediction in hepatocellular carcinoma patients treated with radiotherapy for lymph node metastasis. Br J Radiol 2016;89:20160383. [PMID: 27416997 DOI: 10.1259/bjr.20160383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
470 Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 2009;15:85-94. [PMID: 19098997 DOI: 10.2119/molmed.2008.00110] [Cited by in Crossref: 159] [Cited by in F6Publishing: 164] [Article Influence: 11.4] [Reference Citation Analysis]
471 Xu YY, Chen L, Wang GL, Zhou JM, Zhang YX, Wei YZ, Zhu YY, Qin J. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. BMC Cancer. 2013;13:527. [PMID: 24195809 DOI: 10.1186/1471-2407-13-527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
472 D’Angelo S, Secondulfo M, De Cristofano R, Sorrentino P. Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma? World J Gastroenterol 2013; 19(14): 2141-2143 [PMID: 23599639 DOI: 10.3748/wjg.v19.i14.2141] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
473 Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46. [PMID: 12407575 DOI: 10.1053/jhep.2002.36806] [Cited by in Crossref: 138] [Cited by in F6Publishing: 446] [Article Influence: 6.9] [Reference Citation Analysis]
474 Vizoso F, Rodriguez M, Altadill A, González-Diéguez M, Linares A, González L, Junquera S, Fresno-Forcelledo F, Corte M, Rodrigo L. Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma. World J Gastroenterol 2007; 13(23): 3221-3227 [PMID: 17589901 DOI: 10.3748/wjg.v13.i23.3221] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
475 Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998. [PMID: 18565886 DOI: 10.1200/jco.2007.15.9947.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
476 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
477 Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, Landriscina M. Therapeutic Strategies in HCC: Radiation Modalities. Biomed Res Int. 2016;2016:1295329. [PMID: 27563661 DOI: 10.1155/2016/1295329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
478 Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, Miller CM, Schwartz ME. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-9. [PMID: 11923610 DOI: 10.1097/00000658-200204000-00012] [Cited by in Crossref: 322] [Cited by in F6Publishing: 297] [Article Influence: 16.1] [Reference Citation Analysis]
479 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39:461-472. [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
480 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
481 Seinfeld J, Wagner AS, Kleinschmidt-DeMasters BK. Brain metastases from hepatocellular carcinoma in US patients. J Neurooncol 2006;76:93-8. [PMID: 16402279 DOI: 10.1007/s11060-005-4175-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
482 Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S, Omata M. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216-23. [PMID: 11093727 DOI: 10.1053/jhep.2000.20237] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 4.3] [Reference Citation Analysis]
483 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
484 Ip BC, Wang XD. Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients. 2014;6:124-162. [PMID: 24379011 DOI: 10.3390/nu6010124] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
485 Boudjema K, Compagnon P, Dupont-Bierre E, Lorho R, Lakehal M, Thirouard AS, Meunier B, Messner M. [Liver transplantation for hepatocellular carcinoma]. Cancer Radiother 2005;9:458-63. [PMID: 16223596 DOI: 10.1016/j.canrad.2005.09.009] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
486 Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007;102:1939-46. [PMID: 17573788 DOI: 10.1111/j.1572-0241.2007.01354.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
487 Encke J, Findeklee J, Geib J, Pfaff E, Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 2005;142:362-9. [PMID: 16232225 DOI: 10.1111/j.1365-2249.2005.02919.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
488 Siegel AB, Olsen SK, Magun A, Brown RS Jr. Sorafenib: where do we go from here? Hepatology 2010;52:360-9. [PMID: 20578152 DOI: 10.1002/hep.23633] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
489 Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One 2015;10:e0133515. [PMID: 26214180 DOI: 10.1371/journal.pone.0133515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
490 Chua TC, Saxena A, Chu F, Liauw W, Zhao J, Morris DL. Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients--experience from an Australian hepatobiliary unit. J Gastrointest Surg 2010;14:1370-80. [PMID: 20585991 DOI: 10.1007/s11605-010-1277-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
491 Tsai WL, Lai KH, Liang HL, Hsu PI, Chan HH, Chen WC, Yu HC, Tsay FW, Wang HM, Tsai HC, Cheng JS. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One 2014;9:e92784. [PMID: 24824520 DOI: 10.1371/journal.pone.0092784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
492 Xing S, Kan J, Su A, Liu QD, Wang K, Cai X, Dong J. The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma. Aging (Albany NY) 2019;11:8474-83. [PMID: 31584009 DOI: 10.18632/aging.102333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
493 de Meijer VE, Verhoef C, Kuiper JW, Alwayn IP, Kazemier G, Ijzermans JN. Radiofrequency ablation in patients with primary and secondary hepatic malignancies. J Gastrointest Surg 2006;10:960-73. [PMID: 16843866 DOI: 10.1016/j.gassur.2006.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
494 Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z, Zhang Y, Zhang T. Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci. 2014;59:795-806. [PMID: 24368420 DOI: 10.1007/s10620-013-2969-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
495 Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. Hepatol Int 2009;3:537-43. [PMID: 19669239 DOI: 10.1007/s12072-009-9146-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
496 Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol 2019;54:829-36. [PMID: 31161311 DOI: 10.1007/s00535-019-01595-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
497 Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, Kaseb A. Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma. J Gastrointest Cancer 2015;46:104-8. [PMID: 25645584 DOI: 10.1007/s12029-015-9684-5] [Reference Citation Analysis]
498 Ande A, Chaar M, Ait-Oudhia S. Multiscale systems pharmacological analysis of everolimus action in hepatocellular carcinoma. J Pharmacokinet Pharmacodyn 2018;45:607-20. [PMID: 29725796 DOI: 10.1007/s10928-018-9590-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
499 Alvarez KJ, Smaldone A, Larson EL. Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis. Curr Infect Dis Rep. 2016;18:13. [PMID: 26915098 DOI: 10.1007/s11908-016-0518-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
500 Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) 2013;15:794-802. [PMID: 23782341 DOI: 10.1111/hpb.12134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
501 Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol. 2009;2:45-57. [PMID: 21180533 DOI: 10.1177/1756283X08100328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
502 Jin YJ, Chung YH, Kim JA, Park W, Lee D, Shim JH, Lee D, Kim KM, Lim YS, Lee HC. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci. 2013;58:1758-1765. [PMID: 23361574 DOI: 10.1007/s10620-013-2562-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
503 Bertino G, Ardiri A, Demma S, GiuseppeCalvagno S, Toro A, Basile E, Campagna D, Ferraro G, Frazzetto E, Proiti M. Rare benign tumors of the liver: still rare? J Gastrointest Cancer. 2014;45:202-217. [PMID: 24510731 DOI: 10.1007/s12029-014-9580-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
504 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
505 Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep. 2008;10:199-205. [PMID: 18765149 DOI: 10.1007/s11912-008-0031-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
506 Yeh SA, Chen YS, Perng DS. The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. J Radiat Res 2015;56:325-31. [PMID: 25411553 DOI: 10.1093/jrr/rru104] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
507 Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15:5895-901. [PMID: 19737952 DOI: 10.1158/1078-0432.CCR-09-0465] [Cited by in Crossref: 73] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
508 Zhang Q, Zhang Y, Sun S, Wang K, Qian J, Cui Z, Tao T, Zhou J. ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway. Cell Death Dis 2021;12:15. [PMID: 33414412 DOI: 10.1038/s41419-020-03291-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
509 Koch KS, Leffert HL. Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. Hepat Med 2010;2010:39-47. [PMID: 23997575 DOI: 10.2147/HMER.S7208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
510 Chen YX, Zeng ZC, Fan J, Tang ZY, Zhou J, Zeng MS, Zhang JY, Sun J. Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. Clin Transl Oncol. 2013;15:732-740. [PMID: 23381897 DOI: 10.1007/s12094-012-0997-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
511 Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol 2008; 14(39): 6072-6077 [PMID: 18932288 DOI: 10.3748/wjg.14.6072] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
512 Chok KS, Cheung TT, Chan AC, Dai WC, Chan SC, Lo CM. Liver Resection for De Novo Hepatocellular Carcinoma Complicated by Pyogenic Liver Abscess: A Clinical Challenge. World J Surg 2016;40:412-8. [PMID: 26316116 DOI: 10.1007/s00268-015-3239-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
513 Machairas N, Tsilimigras DI, Moris D. CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe? J Invest Surg 2020;33:542-3. [PMID: 30574819 DOI: 10.1080/08941939.2018.1538399] [Reference Citation Analysis]
514 Queiroz MR, Francisco Neto MJ, Garcia RG, Rahal Junior A, Salvalaggio P, Funari MB. High correlation between microbubble contrast-enhanced ultrasound, magnetic resonance and histopathology in the evaluation of hepatocellular carcinoma. Einstein (Sao Paulo) 2013;11:500-6. [PMID: 24488392 DOI: 10.1590/s1679-45082013000400017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
515 Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy 2012;5:49-54. [PMID: 22826645 DOI: 10.2147/RMHP.S18677] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
516 Saleh DA, Amr S, Jillson IA, Wang JH, Khairy WA, Loffredo CA. Knowledge and perceptions of hepatitis C infection and pesticides use in two rural villages in Egypt. BMC Public Health 2014;14:501. [PMID: 24886607 DOI: 10.1186/1471-2458-14-501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
517 Tezuka M, Hayashi K, Kubota K, Sekine S, Okada Y, Ina H, Irie T. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci. 2007;52:783-788. [PMID: 17268830 DOI: 10.1007/s10620-006-9537-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
518 Kim HJ, Lee HK, Cho JH. Comparison between the treatment area of electrode used for radiofrequency ablation of liver cancer focusing on 15G cooled-tip and CWT electrode. Pak J Med Sci 2016;32:555-8. [PMID: 27375688 DOI: 10.12669/pjms.323.8538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
519 Danos D, Leonardi C, Gilliland A, Shankar S, Srivastava RK, Simonsen N, Ferguson T, Yu Q, Wu XC, Scribner R. Increased Risk of Hepatocellular Carcinoma Associated With Neighborhood Concentrated Disadvantage. Front Oncol 2018;8:375. [PMID: 30254987 DOI: 10.3389/fonc.2018.00375] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
520 Qin HX, Nan KJ, Yang G, Jing Z, Ruan ZP, Li CL, Xu R, Guo H, Sui CG, Wei YC. Expression and clinical significance of TAp73α, p53, PCNA and apoptosis in hepatocellular carcinoma. World J Gastroenterol 2005; 11(18): 2709-2713 [PMID: 15884108 DOI: 10.3748/wjg.v11.i18.2709] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
521 Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005;41:634-42. [PMID: 15726646 DOI: 10.1002/hep.20577] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 6.5] [Reference Citation Analysis]
522 Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. J Gastrointest Surg. 2019;23:101-111. [PMID: 30367397 DOI: 10.1007/s11605-018-4004-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
523 Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009;87:143-52. [PMID: 19136905 DOI: 10.1097/TP.0b013e318191c68d] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
524 Leach MR, Lau D, La Marca F, Park P. Outcomes after surgery for spinal metastasis of colorectal origin: case series. Asian Spine J 2014;8:267-72. [PMID: 24967040 DOI: 10.4184/asj.2014.8.3.267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
525 Chen CY, Lu CL, Chang FY, Wang YY, Jiun KL, Lu RH, Lee SD. Delayed liquid gastric emptying in patients with hepatocellular carcinoma. Am J Gastroenterol 2000;95:3230-7. [PMID: 11095347 DOI: 10.1111/j.1572-0241.2000.03206.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
526 Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003;38:560-6. [PMID: 12939582 DOI: 10.1053/jhep.2003.50375] [Cited by in Crossref: 221] [Cited by in F6Publishing: 171] [Article Influence: 11.6] [Reference Citation Analysis]
527 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
528 Ruggieri A, Franco M, Gatto I, Kumar A, Rapicetta M. Modulation of RANTES expression by HCV core protein in liver derived cell lines. BMC Gastroenterol 2007;7:21. [PMID: 17565659 DOI: 10.1186/1471-230X-7-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
529 Delis SG, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kechagias A, Kelekis D, Madariaga J, Dervenis C. Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria. HPB (Oxford) 2009;11:551-8. [PMID: 20495706 DOI: 10.1111/j.1477-2574.2009.00084.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
530 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
531 Taddei TH, Lo Re V 3rd, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Curr HIV/AIDS Rep 2016;13:269-78. [PMID: 27614654 DOI: 10.1007/s11904-016-0327-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
532 Liu Y, Lan L, Li Y, Lu J, He L, Deng Y, Fei M, Lu JW, Shangguan F, Lu JP, Wang J, Wu L, Huang K, Lu B. N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth. Redox Biol 2022;54:102366. [PMID: 35728303 DOI: 10.1016/j.redox.2022.102366] [Reference Citation Analysis]
533 Huang J, Hernandez-Alejandro R, Croome KP, Yan L, Wu H, Chen Z, Prasoon P, Zeng Y. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases. J Gastrointest Surg. 2011;15:311-320. [PMID: 21052859 DOI: 10.1007/s11605-010-1372-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
534 Kemeny NE, Schwartz L, Gönen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011;80:153-9. [PMID: 21677464 DOI: 10.1159/000324704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
535 Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2:191-200. [PMID: 30190998 DOI: 10.2217/hep.15.6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
536 Lee CF, Ling ZQ, Zhao T, Fang SH, Chang WC, Lee SC, Lee KR. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J Gastroenterol 2009; 15(3): 356-365 [PMID: 19140237 DOI: 10.3748/wjg.15.356] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
537 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 251] [Article Influence: 30.9] [Reference Citation Analysis]
538 Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91:31-37. [PMID: 11189820 DOI: 10.2105/ajph.91.1.31] [Cited by in Crossref: 310] [Cited by in F6Publishing: 139] [Article Influence: 14.8] [Reference Citation Analysis]
539 Bian Q, Zhang X, Wang Z, Liu M, Li B, Wu D, Liu G, Kim YH. Virtual surgery system for liver tumor resection. IFS 2020;38:263-76. [DOI: 10.3233/jifs-179401] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
540 Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: a case report and review of the literature. Am J Gastroenterol 2003;98:201-4. [PMID: 12526959 DOI: 10.1111/j.1572-0241.2003.07183.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
541 Siegel AB, McBride RB, El-Serag HB, Hershman D, Brown RS Jr, Zablotska L, Neugut AI. The risk of hepatocellular carcinoma in patients with previous malignancy. Cancer Invest 2008;26:511-5. [PMID: 18568774 DOI: 10.1080/07357900701788007] [Reference Citation Analysis]
542 Griffin N, Addley H, Sala E, Shaw AS, Grant LA, Eldaly H, Davies SE, Prevost T, Alexander GJ, Lomas DJ. Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI? Br J Radiol 2012;85:736-44. [PMID: 21385912 DOI: 10.1259/bjr/94924398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
543 Gehlot P, Shukla V, Gupta S, Makidon PE. Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells. J Transl Med 2016;14:49. [PMID: 26873175 DOI: 10.1186/s12967-016-0785-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
544 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 131] [Article Influence: 3.5] [Reference Citation Analysis]
545 Zhang X, Zhou X, Hara T, Fujita H. Non-Invasive Assessment of Hepatic Fibrosis by Elastic Measurement of Liver Using Magnetic Resonance Tagging Images. Applied Sciences 2018;8:437. [DOI: 10.3390/app8030437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
546 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14(27): 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300] [Cited by in CrossRef: 434] [Cited by in F6Publishing: 403] [Article Influence: 31.0] [Reference Citation Analysis]
547 Mas VR, Maluf DG, Archer KJ, Yanek K, Williams B, Fisher RA. Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med 2006;12:97-104. [PMID: 16953559 DOI: 10.2119/2006-00032.Mas] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
548 Ellis JM, Paul DS, Depetrillo MA, Singh BP, Malarkey DE, Coleman RA. Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibility to liver cancer. Toxicol Pathol 2012;40:513-21. [PMID: 22215515 DOI: 10.1177/0192623311432298] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
549 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 49] [Article Influence: 14.8] [Reference Citation Analysis]
550 Manos MM, Leyden WA, Murphy RC, Terrault NA, Bell BP. Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology 2008;47:1150-7. [PMID: 18264998 DOI: 10.1002/hep.22181] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
551 Yuan Y, Wang J, Li J, Wang L, Li M, Yang Z, Zhang C, Dai JL. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin Cancer Res. 2006;12:6687-6695. [PMID: 17121887 DOI: 10.1158/1078-0432.ccr-06-0921] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
552 Pan HY, Wu QQ, Yin QQ, Dai YN, Huang YC, Zheng W, Hui TC, Chen MJ, Wang MS, Zhang JJ, Huang HJ, Tong YX. LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis. ACS Omega 2021;6:1160-70. [PMID: 33490775 DOI: 10.1021/acsomega.0c04259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Yalamanchili K, Saadeh S, Lepe R, Davis GL. The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) 2005;18:3-6. [PMID: 16200141 DOI: 10.1080/08998280.2005.11928024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
554 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med. 2015;4:1836-1843. [PMID: 26471348 DOI: 10.1002/cam4.548] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
555 Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO, Tsubouchi H. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 2007;45:948-56. [PMID: 17393466 DOI: 10.1002/hep.21598] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
556 Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, Wakasa K, Zhou J, Fan J, Tang ZY, Fu S, Zhu H, Jin JG, Sun HC, Wang XW. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci 2013;9:303-12. [PMID: 23569435 DOI: 10.7150/ijbs.6214] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
557 Shin SW, Jeong WK, Lim S, Kim Y, Kim J. Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume. Clin Mol Hepatol 2015;21:71-9. [PMID: 25834804 DOI: 10.3350/cmh.2015.21.1.71] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
558 Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, Grant DR, Greig PD. Prognosis and results after resection of very large (>or=10 cm) hepatocellular carcinoma. J Gastrointest Surg. 2007;11:589-595. [PMID: 17393258 DOI: 10.1007/s11605-007-0154-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
559 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
560 Venook AP. Hepatocellular carcinoma. Curr Treat Options Oncol. 2000;1:407-415. [PMID: 12057148 DOI: 10.1007/s11864-000-0068-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
561 Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis. Oncogene 2012;31:842-57. [PMID: 21743491 DOI: 10.1038/onc.2011.287] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
562 Balendiran GK, Martin HJ, El-Hawari Y, Maser E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact 2009;178:134-7. [PMID: 19028477 DOI: 10.1016/j.cbi.2008.10.044] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
563 Xiang ZL, Zeng ZC, Tang ZY, Fan J, He J, Zeng HY, Zhu XD. Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma. Oncologist 2011;16:1028-39. [PMID: 21665914 DOI: 10.1634/theoncologist.2010-0358] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
564 Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011;53:1570-9. [PMID: 21520172 DOI: 10.1002/hep.24231] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 9.1] [Reference Citation Analysis]
565 Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcinoma. J Gastrointest Cancer. 2011;42:191-194. [PMID: 20820946 DOI: 10.1007/s12029-010-9195-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
566 Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13. [PMID: 12395331 DOI: 10.1053/jhep.2002.36780] [Cited by in Crossref: 538] [Cited by in F6Publishing: 485] [Article Influence: 26.9] [Reference Citation Analysis]
567 Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif. 2009;42:229-240. [PMID: 19317806 DOI: 10.1111/j.1365-2184.2008.00581.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
568 Afzal M, Kazmi I, Gupta G, Rahman M, Kimothi V, Anwar F. Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. Saudi Pharm J 2012;20:365-70. [PMID: 23960811 DOI: 10.1016/j.jsps.2012.05.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
569 Tsoulfas G, Kawai T, Elias N, Ko SC, Agorastou P, Cosimi AB, Hertl M. Long-term experience with liver transplantation for hepatocellular carcinoma. J Gastroenterol 2011;46:249-56. [PMID: 20711612 DOI: 10.1007/s00535-010-0302-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
570 Sayana H, Yousef O, Clarkston WK. Massive upper gastrointestinal hemorrhage due to invasive hepatocellular carcinoma and hepato-gastric fistula. World J Gastroenterol 2013; 19(42): 7472-7475 [PMID: 24259980 DOI: 10.3748/wjg.v19.i42.7472] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
571 Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003;37:65-71. [PMID: 12500190 DOI: 10.1053/jhep.2003.50017] [Cited by in Crossref: 128] [Cited by in F6Publishing: 122] [Article Influence: 6.7] [Reference Citation Analysis]
572 Qi F, Zhou A, Yan L, Yuan X, Wang D, Chang R, Zhang Y, Shi F, Han X, Hou J, Wei L, Zhang X. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23158. [PMID: 31821607 DOI: 10.1002/jcla.23158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
573 Ahn DW, Shim JH, Yoon JH, Kim CY, Lee HS, Kim YT, Kim YJ. Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma. Korean J Hepatol. 2011;17:106-112. [PMID: 21757981 DOI: 10.3350/kjhep.2011.17.2.106] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
574 Hashim M, Salem AA. Simultaneous treatment of unresectable hepatocelluar carcinoma and hepatic artery aneurysm, case report. J Gastrointest Cancer 2010;41:13-6. [PMID: 20020225 DOI: 10.1007/s12029-009-9117-4] [Reference Citation Analysis]
575 Singh S, Singh PP. Statins for prevention of hepatocellular cancer: one step closer? Hepatology 2014;59:724-6. [PMID: 23839991 DOI: 10.1002/hep.26614] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
576 El-Zayadi AR, Badran HM, Shawky S, Emara S, El-Bareedy A, Sobhi M. Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol Int 2010;4:500-6. [PMID: 20827407 DOI: 10.1007/s12072-010-9170-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
577 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
578 Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS One 2014;9:e105679. [PMID: 25153834 DOI: 10.1371/journal.pone.0105679] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
579 Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9. [PMID: 21911725 DOI: 10.1200/JCO.2011.36.0636] [Cited by in Crossref: 83] [Cited by in F6Publishing: 54] [Article Influence: 7.5] [Reference Citation Analysis]
580 Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement.J Hepatocell Carcinoma. 2017;4:29-39. [PMID: 28255543 DOI: 10.2147/JHC.S125396] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
581 Esteban R. Can interferon prolong life? Hepatology 2003;38:292-4. [PMID: 12883472 DOI: 10.1053/jhep.2003.50337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
582 Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014;12:738-48. [PMID: 23811241 DOI: 10.1016/j.cgh.2013.06.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
583 Gassmann P, Spieker T, Haier J, Schmidt F, Mardin WA, Senninger N. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010;34:2442-51. [PMID: 20544346 DOI: 10.1007/s00268-010-0655-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
584 Nam SY. Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver 2017;11:323-34. [PMID: 27890867 DOI: 10.5009/gnl15557] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
585 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
586 Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 2003;237:376-383. [PMID: 12616122 DOI: 10.1097/01.sla.0000055224.68432.80] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
587 Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007;102:1510-7. [PMID: 17509025 DOI: 10.1111/j.1572-0241.2007.01286.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 136] [Article Influence: 9.9] [Reference Citation Analysis]
588 Xu RH, Gao W, Wang C, Guo DK, Tang L, Zhang H, Wang CJ. Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis. Eur J Med Res 2014;19:39. [PMID: 25141776 DOI: 10.1186/2047-783X-19-39] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
589 Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-42. [PMID: 12085369 DOI: 10.1053/jhep.2002.34734] [Cited by in Crossref: 415] [Cited by in F6Publishing: 384] [Article Influence: 20.8] [Reference Citation Analysis]
590 Reichman TW, Bahramipour P, Barone A, Koneru B, Fisher A, Contractor D, Wilson D, Dela Torre A, Cho KC, Samanta A. Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. J Gastrointest Surg. 2005;9:638-645. [PMID: 15862257 DOI: 10.1016/j.gassur.2004.11.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
591 Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol. 2010;52:690-697. [PMID: 20338660 DOI: 10.1016/j.jhep.2009.12.025] [Cited by in Crossref: 139] [Cited by in F6Publishing: 145] [Article Influence: 11.6] [Reference Citation Analysis]
592 Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15:285-292. [PMID: 20203173 DOI: 10.1634/theoncologist.2009-0316] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 5.7] [Reference Citation Analysis]
593 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 13.3] [Reference Citation Analysis]
594 Tomimaru Y, Wada H, Eguchi H, Tomokuni A, Hama N, Kawamoto K, Marubashi S, Umeshita K, Doki Y, Mori M, Wakasa K, Nagano H. Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma. Surg Today. 2015;45:1112-1120. [PMID: 25205550 DOI: 10.1007/s00595-014-1028-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
595 Zhu X, Wu X, Cheng J, Liao H, Di X, Li L, Li R, Zhou Y, Zhang X. Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells. Oncotarget 2017;8:47755-66. [PMID: 28548956 DOI: 10.18632/oncotarget.17766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
596 Cabibbo G, Craxì A. Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J Hepatol 2009; 1(1): 62-66 [PMID: 21160966 DOI: 10.4254/wjh.v1.i1.62] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
597 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
598 Chen G, Chen H, Huang X, Cheng S, Zheng S, Wu Y, Zheng T, Chen X, Guo X, Zhang Z, Xie X, Zhang B. Recurrence Outcome in Hepatocellular Carcinoma within Milan Criteria Undergoing Microwave Ablation with or without Transarterial Chemoembolization. Medicina 2022;58:1016. [DOI: 10.3390/medicina58081016] [Reference Citation Analysis]
599 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-438 [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 15.2] [Reference Citation Analysis]
600 Kaibori M, Matsui K, Ishizaki M, Iida H, Yoshii K, Asano H, Kon M. Effects of implementing an "enhanced recovery after surgery" program on patients undergoing resection of hepatocellular carcinoma. Surg Today 2017;47:42-51. [PMID: 27165267 DOI: 10.1007/s00595-016-1344-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
601 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A, Saito S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 2012; 18(16): 1933-1939 [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
602 Tiong LU, Finnie JW, Field JB, Maddern GJ. Bimodal electric tissue ablation (BETA)--effect of reversing the polarity of the direct current on the size of ablation. J Surg Res 2012;174:305-11. [PMID: 21392803 DOI: 10.1016/j.jss.2011.01.013] [Reference Citation Analysis]
603 Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, Han JK, Choi BI. Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT: comparison with pathological differentiation. Br J Radiol. 2012;85:e573-e583. [PMID: 22919011 DOI: 10.1259/bjr/86767895] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
604 Anaya DA, Blazer DG, Abdalla EK. Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Intervent Radiol 2008;25:110-22. [PMID: 21326552 DOI: 10.1055/s-2008-1076684] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
605 Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9:31. [PMID: 19432967 DOI: 10.1186/1471-230x-9-31] [Cited by in Crossref: 101] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
606 Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000;31:899-906. [PMID: 10733546 DOI: 10.1053/he.2000.5763] [Cited by in Crossref: 239] [Cited by in F6Publishing: 232] [Article Influence: 10.9] [Reference Citation Analysis]
607 Koido S, Homma S, Hara E, Mitsunaga M, Namiki Y, Takahara A, Nagasaki E, Komita H, Sagawa Y, Ohkusa T, Fujise K, Gong J, Tajiri H. In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. J Transl Med 2008;6:51. [PMID: 18793383 DOI: 10.1186/1479-5876-6-51] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
608 Hong HP, Lee JY, Lee MY, Jung KU, Kim BI, Son BH, Shin JH, Lee SR. Early experience with laparoscopic treatment of liver tumors using a separable cluster electrode with a no-touch technique. Wideochir Inne Tech Maloinwazyjne 2021;16:76-82. [PMID: 33786119 DOI: 10.5114/wiitm.2020.95065] [Reference Citation Analysis]
609 Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4255] [Cited by in F6Publishing: 3974] [Article Influence: 250.3] [Reference Citation Analysis]
610 Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, Mine N, Kondo Y, Kawabe T, Omata M. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006;43:1101-8. [PMID: 16628706 DOI: 10.1002/hep.21164] [Cited by in Crossref: 225] [Cited by in F6Publishing: 208] [Article Influence: 14.1] [Reference Citation Analysis]
611 Ji J, Hemminki K. Variation in the risk for liver and gallbladder cancers in socioeconomic and occupational groups in Sweden with etiological implications. Int Arch Occup Environ Health 2005;78:641-9. [PMID: 16001211 DOI: 10.1007/s00420-005-0015-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
612 Norén A, Urdzik J, Duraj F, Barbier CE, Karlson BM, Haglund U. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB (Oxford) 2010;12:637-43. [PMID: 20961372 DOI: 10.1111/j.1477-2574.2010.00210.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
613 Su YC, Davuluri GV, Chen CH, Shiau DC, Chen CC, Chen CL, Lin YS, Chang CP. Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma. PLoS One 2016;11:e0148408. [PMID: 26859293 DOI: 10.1371/journal.pone.0148408] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
614 Nair S, Shiv Kumar K, Thuluvath PJ. Mortality from hepatocellular and biliary cancers: changing epidemiological trends. Am J Gastroenterol 2002;97:167-71. [PMID: 11808943 DOI: 10.1111/j.1572-0241.2002.05432.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
615 Kaibori M, Shikata N, Sakaguchi T, Ishizaki M, Matsui K, Iida H, Tanaka Y, Miki H, Nakatake R, Okumura T. Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2015;60:919-928. [PMID: 25371154 DOI: 10.1007/s10620-014-3417-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
616 Wong LL, Tsai N. Hepatocellular carcinoma in Filipinos. Asia-Pacific J Clinical Oncology 2007;3:84-8. [DOI: 10.1111/j.1743-7563.2007.00091.x] [Reference Citation Analysis]
617 Mckiver B, Damaj MI, Sarkar D. Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma. GastrointestDisord 2020;2:469-80. [DOI: 10.3390/gidisord2040042] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
618 Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005;100:56-63. [PMID: 15654781 DOI: 10.1111/j.1572-0241.2005.40670.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
619 Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, Fallon J, Mandeli J, Woo SL. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 2009;16:266-78. [PMID: 18846115 DOI: 10.1038/cgt.2008.74] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
620 Kasai K, Ushio A, Sawara K, Miyamoto Y, Kasai Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol 2010; 16(27): 3437-3444 [PMID: 20632449 DOI: 10.3748/wjg.v16.i27.3437] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
621 Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007;1:316-25. [PMID: 19669356 DOI: 10.1007/s12072-007-9006-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
622 Park YK, Kim KM, Lee YJ, Kim KH, Lee SG, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci 2011;26:214-21. [PMID: 21286012 DOI: 10.3346/jkms.2011.26.2.214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
623 Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-9. [PMID: 11772974 DOI: 10.1136/gut.50.1.95] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 4.8] [Reference Citation Analysis]
624 Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
625 Koike Y, Yoshida H, Shiina S, Teratani T, Obi S, Sato S, Akamatsu M, Tateishi R, Fujishima T, Hoshida Y, Kanda M, Ishikawa T, Shiratori Y, Omata M. Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. Hepatol Int 2007;1:295-301. [PMID: 19669353 DOI: 10.1007/s12072-007-9001-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
626 Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein tumor thrombosis. World J Gastroenterol 2003; 9(12): 2666-2670 [PMID: 14669309 DOI: 10.3748/wjg.v9.i12.2666] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
627 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
628 Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol. 2011;137:139-149. [PMID: 20340033 DOI: 10.1007/s00432-010-0868-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
629 Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial. Am J Gastroenterol. 2013;108:1305-1313. [PMID: 23629602 DOI: 10.1038/ajg.2013.109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
630 Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci. 2008;53:809-814. [PMID: 17823868 DOI: 10.1007/s10620-007-9926-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
631 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol 2013; 5(6): 311-322 [PMID: 23805355 DOI: 10.4254/wjh.v5.i6.311] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
632 Matumba L, Kimanya M, Chunga-sambo W, Munthali M, Ayalew A. Probabilistic dietary based estimation of the burden of aflatoxin-induced hepatocellular carcinoma among adult Malawians. World Mycotoxin Journal 2019;12:409-19. [DOI: 10.3920/wmj2018.2346] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
633 Naylor PH, Mutchnick M. Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C. Hepat Med 2017;9:13-6. [PMID: 28356778 DOI: 10.2147/HMER.S118063] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
634 Suk FM, Lien GS, Huang WJ, Chen CN, Lu SY, Yang YC, Yan MD, Liang YC. A Taiwanese Propolis Derivative Induces Apoptosis through Inducing Endoplasmic Reticular Stress and Activating Transcription Factor-3 in Human Hepatoma Cells. Evid Based Complement Alternat Med 2013;2013:658370. [PMID: 24222778 DOI: 10.1155/2013/658370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
635 Megger DA, Bracht T, Kohl M, Ahrens M, Naboulsi W, Weber F, Hoffmann AC, Stephan C, Kuhlmann K, Eisenacher M, Schlaak JF, Baba HA, Meyer HE, Sitek B. Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. Mol Cell Proteomics 2013;12:2006-20. [PMID: 23462207 DOI: 10.1074/mcp.M113.028027] [Cited by in Crossref: 81] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
636 Wang H, Liu Y, Xu M, Cheng J. Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma. Biomater Sci 2019;7:4166-73. [PMID: 31368459 DOI: 10.1039/c9bm00898e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
637 Wu ZM, Dai C, Huang Y, Zheng CF, Dong QZ, Wang G, Li XW, Zhang XF, Li B, Chen G. Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines. Acta Pharmacol Sin 2011;32:939-46. [PMID: 21666704 DOI: 10.1038/aps.2011.28] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
638 Han JH, Kim DG, Park JC, Chung HT, Paek SH, Chung, YS. Little response of cerebral metastasis from hepatocellular carcinoma to any treatments. J Korean Neurosurg Soc. 2010;325-331. [PMID: 20539790 DOI: 10.3340/jkns.2010.47.5.325] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
639 Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 coinfection. Gut 2002;51:601-8. [PMID: 12235089 DOI: 10.1136/gut.51.4.601] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 3.1] [Reference Citation Analysis]
640 Hernandez BY, Zhu X, Kwee S, Chan OT, Tsai N, Okimoto G, Horio D, McGlynn KA, Altekruse S, Wong LL. Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:2016-23. [PMID: 23983238 DOI: 10.1158/1055-9965.EPI-13-0397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
641 Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020;158:1822-30. [PMID: 32006545 DOI: 10.1053/j.gastro.2019.12.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 60] [Article Influence: 24.5] [Reference Citation Analysis]
642 Kloeckner R, Pinto Dos Santos D, Kreitner KF, Leicher-Düber A, Weinmann A, Mittler J, Düber C. Quantitative assessment of washout in hepatocellular carcinoma using MRI. BMC Cancer 2016;16:758. [PMID: 27681525 DOI: 10.1186/s12885-016-2797-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
643 Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z. Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci. 2014;59:795-806. [PMID: 24368420 DOI: 10.1007/s10620-013-2969-2.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
644 Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu Y, Huang XW, Tang ZY. Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:715-722. [PMID: 19002496 DOI: 10.1007/s00432-008-0506-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
645 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
646 Wilson JM, Shchelochkov OA, Gallagher RC, Batshaw ML. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab. 2012;105:263-265. [PMID: 22129577 DOI: 10.1016/j.ymgme.2011.10.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
647 Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol 2016; 22(1): 394-406 [PMID: 26755885 DOI: 10.3748/wjg.v22.i1.394] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
648 Rich NE, Yopp AC, Singal AG, Murphy CC. Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. Clin Gastroenterol Hepatol 2020;18:242-248.e5. [PMID: 31042582 DOI: 10.1016/j.cgh.2019.04.043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
649 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [78495111110.1046/j.1365-2036.17.s2.21.x','', '1007-9327')">Reference Citation Analysis]
650 Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465. [PMID: 26059447 DOI: 10.1186/s12885-015-1480-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
651 Park MJ, Kim YK, Lee MH, Lee JH. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol 2013;54:127-36. [PMID: 23148300 DOI: 10.1258/ar.2012.120262] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
652 Schwarz KB, Kew M, Klein A, Abrams RA, Sitzmann J, Jones L, Sharma S, Britton RS, Di Bisceglie AM, Groopman J. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig Dis Sci 2001;46:2173-8. [PMID: 11680593 DOI: 10.1023/a:1011958814371] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
653 Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L, Pomier-Layrargues G. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol. 2011;2011:974514. [PMID: 21994880 DOI: 10.4061/2011/974514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
654 Notarnicola M, Messa C, Refolo MG, Tutino V, Miccolis A, Caruso MG. Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line. Lipids Health Dis 2011;10:10. [PMID: 21244676 DOI: 10.1186/1476-511X-10-10] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
655 Qu L, Kuai X, Liu T, Chen T, Ni Z, Shen X. Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. PLoS One 2013;8:e59583. [PMID: 23555717 DOI: 10.1371/journal.pone.0059583] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
656 Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl. 2012;18:1471-1478. [PMID: 23008049 DOI: 10.1002/lt.23551] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
657 Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-672. [PMID: 16802842 DOI: 10.2165/00019053-200624070-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
658 Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A, Fornari F, Del Vecchio Blanco C, de Sio I. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004;53:1356-62. [PMID: 15306600 DOI: 10.1136/gut.2003.032359] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
659 Puglisi F, Aprile G, Fasola G. Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology. Anticancer Drugs 2008;19:221-33. [PMID: 18176120 DOI: 10.1097/CAD.0b013e3282f2c938] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
660 Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ, Ross PJ. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer 2013;109:888-90. [PMID: 23880824 DOI: 10.1038/bjc.2013.410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
661 Delis S, Bramis I, Triantopoulou C, Madariaga J, Dervenis C. The imprint of radiofrequency in the management of hepatocellular carcinoma. HPB (Oxford) 2006;8:255-63. [PMID: 18333136 DOI: 10.1080/13651820500273673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
662 Hu K, Wang J, Yao Z, Liu B, Lin Y, Liu L, Xu L. Expression of cytoskeleton regulatory protein Mena in human hepatocellular carcinoma and its prognostic significance. Med Oncol 2014;31:939. [PMID: 24683008 DOI: 10.1007/s12032-014-0939-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
663 Yang J, Yang Y, Tian L, Sheng XF, Liu F, Cao JG. Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. World J Gastroenterol 2011; 17(38): 4298-4307 [PMID: 22090786 DOI: 10.3748/wjg.v17.i38.4298] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
664 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15(26): 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 96] [Article Influence: 7.2] [Reference Citation Analysis]
665 Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7. [PMID: 12601348 DOI: 10.1053/jhep.2003.50093] [Cited by in Crossref: 307] [Cited by in F6Publishing: 265] [Article Influence: 16.2] [Reference Citation Analysis]
666 Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors. World J Surg. 2015;39:1150-1160. [PMID: 25634340 DOI: 10.1007/s00268-015-2956-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
667 Pollock BH, Elmore S, Romoser A, Tang L, Kang MS, Xue K, Rodriguez M, Dierschke NA, Hayes HG, Hansen HA, Guerra F, Wang JS, Phillips T. Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2016;33:1346-54. [PMID: 27321368 DOI: 10.1080/19440049.2016.1198498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
668 García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179-83. [PMID: